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INTRODUCTION TO THE THESIS 
The major impact of recent clinical research with interleukin-2 (IL2) has been 
the demonstration that a strictly immunological manipulation can mediate the 
regression of established cancer in humans through the activation of cytotoxic 
lymphocytes and the release of secondary cytokines. 
Since 1985 a variety of clinical studies have been carried out in metastatic 
cancer patients with the use of interleukins, interferons, and Iymphokine activated 
killer cells. These studies have either employed a single agent approach or 
combined modality treatment also including hormonal and chemotherapy. 
Although the majority of human cancers are systemic diseases by nature, 
some tumor types are predilected to reside in one organ site or cavity. For 
example, metastatic colon cancer is often confined to the liver for prolonged 
periods of time. Ovarian cancer is usually restricted to the abdominal cavity, 
whereas mesothelioma mostly does not extend the pleural cavity until death. 
It is for these reasons that the clinical investigations described in this thesis 
are based on a systemic approach on the one hand and on a locoregional 
approach on the other hand in selected tumor types. The study treatments 
comprised single agent IL2 and combinations of IL2 and interferon (IFN)-a with or 
without chemotherapy. 
Regarding the systemic administration of IL2 based immunotherapy, we have 
chosen for a constant infusion schedule rather than intermittent bolus intravenous 
administration, based on available data in the literature of treatment equivalence 
and less toxicity accompanied with the continuous infusion method. 
For the locoregional treatment of liver metastases we have used a 
continuous arterial infusion method. It appeared that intra-arterial as well as 
peripheral intravenous administration of IL2 resulted in endothelial damage leading 
to thrombophlebitis and thromboembolic complications. These untowards side 
effects have led us to use central venous catheters (CVCs) for the administration 
of IL2 in the treatment of systemic disease. In principle, this approach will reduce 
the risk of thromboembolic complications, but create a new problem, namely the 
occurrence of catheter related infections. Consequently, we have investigated the 
safety of tunneled CVCs. 
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Chapter 1 
INTRODUCTION 
Renal cell cancer (RCC) is a disease afflicting approximately 27,000 
individuals per year in the United States (1). It is the 10~ most common cancer, 
constitutes 3% of all adult malignancies, affects men more than women, and 
occurs at a median age of 64 years. One third of the patients presents with distant 
metastases while 30-40% of the others will eventually develop these (2). The 
median survival of metastatic disease is 7 months and only 1-2% of patients 
survive 5 years or more (3). Surgery is the standard treatment for localized 
disease; however, its role in the presence of distant metastases is limited to 
palliation of symptoms or resection of solitary metastases in highly selected 
patients. The role of radiotherapy is limited to palliation of symptoms, while 
hormonal treatment and chemotherapy are ineffective (4), the latter possibly partly 
because of the high expression of the multidrug resistance (MDR1) gene in human 
RCC (5). 
In search for better treatment immunotherapy has also been studied 
extensively. The basis for this approach originated from observations that 
metastases though infrequently (6), may regress following nephrectomy as a 
consequence of an immune response. Early attempts to induce an immune 
response involved application of crude tumor cell preparations, bacillus Calmette-
Guerin, or Corynebacterium parvum. Such non-specific immunotherapy was 
proven ineffective (7). Efforts were subsequently directed towards activation of the 
patients' immune system by biologic response modifiers (BRMs) or the adoptive 
transfer of activated immune cells. The interest in immunotherapy revived with the 
potentials of genetic engineering, mass cell culturing, the improved techniques in 
protein and nucleic acid sequencing, and hybridoma technology (8) through which 
highly purified molecules such as interferons, interleukins, tumor-necrosis factor 
and monoclonal antibodies directed against tumor-associated antigens became 
available. In renal cell cancer the most significant treatment results are obtained 
with interferons and interleukin-2. This review focuses on the use of these 
cytokines. 
IMMUNOMODULATION WITH INTERFERON 
Interferons were initially identified as antiviral agents (9), but in addition these 
molecules are potent regulators of cell gene expression, cell structure and cell 
function, and they exhibit direct antiproliferative activity. Three major classes of 
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interferons have been characterized: Interferon-alpha (IFN-a) produced by 
leukocytes, interferon-beta (lFN-fI) produced by fibroblasts, Iymphoblastoid cells, 
macrophages and epithelial cells, and interferon-gamma (IFN-y) produced by 
activated lymphocytes. Interferons have antitumor properties, either mediated 
through a direct cytotoxic effect on tumor cells, augmentation of the 
immunogenicity of tumors by upregulation of major histocompatibility complex 
(MHC) and tumor-associated antigens, and/or activation of macrophages, T-
lymphocytes, and natural killer (NK) cells. 
Initially, human leukocyte derived IFN-a was used (10-12), yielding response 
rates not exceeding 15% in patients with renal cell cancer. The development of 
recombinant DNA techniques made it possible to develop highly purified 
preparations with considerable biologic activity. Studies using IFNa-2a have shown 
response rates of approximately 15% (a total of 420 patients; 95% confidence 
interval (CI) of 12-19%) (13-21). With IFNa-2b similar response rates have been 
reported (239 patients; 95% CI of 12-22%) (17, 22-25). The experience with IFN-P 
in renal cell cancer is very limited (response rate of 7% in only 28 patients) 
(26,27). IFN-y yielded a 10% response rate (255 patients;95% CI of 6-14%) 
(23,28-36). In most series, patients with a good performance status, low tumor 
burden or mainly lung metastases were more likely to respond to IFN. The time to 
response varied from 1-3 months, the median duration of response was 6 months. 
Survival data vary from 7-18' months and are likely to be influenced by patient 
selection (15,37). 
In a meta-analysis of 1600 RCC patients, treatment with IFN resulted in a 
response rate of 15% including 2% complete responses (38). Approximately 3% of 
responding patients survived for prolonged periods without additional therapy. 
Selection bias and small sample size may account for much of the variability in 
reported response rates. 
Although the optimal dose and schedule of IFN-a has yet to be determined, 
in 2 small randomized trials the highest therapeutic index was achieved with a 
total daily dose of 5-10 MU (12,13,39). The route of administration (s.c. or i.v.) 
does not seem to be a major factor in determining response. 
Side effects of interferon therapy are proportional to dose, more pronounced 
in elderly patients and fully reversible (40). Acute effects involve an influenza-like 
syndrome, characterized by fever, chills, tachycardia, malaise, myalgia, headache, 
dizziness, but dissipate after 1 week of continued therapy. Chronic effects involve 
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primarily fatigue, weakness, and anorexia, which have been dose-limiting in the 
majority of trials. Other common and usually mild side effects include decreased 
ability to concentrate, nausea, emesis, diarrhea,. elevation of liver enzymes, 
proteinuria, alopecia, anemia, leukopenia, and thrombocytopenia (40). Moderate to 
severe changes in behavior are possibly due to direct effects of IFN on the brain 
(41,42). Toxicity can be reduced by using induction treatment with relatively high 
dose over a short period of time followed by maintenance therapy with a lower 
dose (15). Patients can be treated symptomatically with acetaminophen and 
benzodiazepines. The development of neutralizing anti-interferon antibodies in 
patients during therapy with IFN has been described. The observed frequency 
showed a wide range, varying from 5 to 44% (13,22,43,44). The clinical relevance 
of these antibodies remains controversial and further investigations are necessary 
to determine the effect of their formation on antitumor response. 
It has been suggested that treatment results with IFN-a may be improved by 
the addition of cytotoxic drugs, in particular vinblastine, which is considered to 
have some activity in Ree (46). However, while response rates in relatively small 
non randomized studies range from 0-45%, a randomized study (47) could not 
show any benefit of adding vinblastine to IFN-a. 
In conclusion, single agent therapy with interferon in metastatic renal cell 
cancer manifests modest clinical antitumor activity. It is not clear whether anyone 
IFN preparation or dosage scheme is superior, nor is there definitive evidence for 
the superior efficacy of interferon combinations or interferon in conjunction with 
chemotherapy. 
THE INTERLEUKINS 
The interleukins are mediators secreted by a variety of cell types that can 
activate and regulate growth and/or differentiation of immune cells. Through 
recombinant DNA technology the list of known, well-characterized, multifunctional 
interleukins has extended steadily. To date, 15 interleukins have been identified 
and cloned (Table 1). The availability of purified, recombinant interleukins has 
enabled extensive in vitro and in vivo studies, to characterize their biologic effects 
and mechanisms of action. This has considerably enhanced our understanding of 
how these multifunctional cytokines regulate immune-, hematopoietic- and 
inHammatory processes, through binding to unique cell surface receptors. In most 
instances the action of one particular cytokine can cause a cascade of events in 
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Table 1 The Interleuklnes 
Inlerleukin(s) Source Biologic effects Ref. 
1L1 Monocytesfmacrophages; Costimulates B-cell proliferation; induces 48-50 
dendritic cells; B, T, and NK maturation of pre-B-cells; induces IL2 
cells; keratinocytes; production, increases IL2 receptor number and 
fibroblasts; endothelial cells; binding on T-cells, augments T-cell-derived 
epithelial cells; glial cells; Iymphokine-aclivated killer (T-LAK) activity; 
neuronal cells activates macrophages; induces acute phase 
responses 
IL2 T-ceUs Costimulates T -cells; activates cytotoxic 51-54 
responses and chemotaxis of T-ceUs; co-factor 
for growth and differentiation of B-cells; 
generates NK-derived LAK cells 
IL3 T-cells; thymic epithelium; Stimulates early progenitor cell growth; 55-59 
myelomonocytic cells; synergizes with Steel factor for early 
keratinocytes; neuronal cells multipotential progenitor cell expansion; B-cell 
differentiation; augments LAK-activity in the 
presence of IL2 
IL4 T -cells; mast cells; B-cell growth factor; induces MHC class II 57, 
macrophages; bone marrow antigens on monocytes and B-cells; activation of 60-63 
stroma IL2 stimulated LAK cells; synergizes with 1L12 in 
NK cell proliferation 
IL5 T-cells; mast cells Induces IL2 receptor on T-cells, B-cells and NK- 57,61, 
cells; B-cell growth factor II; increases IgA and 64, 65 
IgM secretion; co-factor for induction of CTL 
differentiation; induces proliferation and 
differentiation of eosinophils 
IL6 T-celfs; monocytes; B-cell differentiation factor; co-stimulator of T- 66-70 
fibroblasts; endothelial cells; cells; induces IL2 production; megakaryocyte 
tumor cells differentiation factor; induction of acute phase 
proteins; activates NK-ceJls 
IL7 Bone marrow stromal cells Supports the growth of B-cell precursors; 63, 
induces cytokine secretion and tumoricidal 71-73 
activity by monocytes; maintains viability and 
responsiveness 10 IL2 of NK precusors 
IL8 Monocytes Chemoattraclanl for neulrophils 74 
IL9 T -helper cells Stimulates proliferation of mitogen activated T- 75-77 
cells; potentiates IL4 induced IgE synthesis by 
B-cells; supports erythroid colony formation 
1L10 T -cells; B-cells; macrophages Cytokine synthesis inhibitory faclor for T-helper 78-80 
cells; costimulates with IL2 and IL4 the 
proliferation of activated T -cells; augments CTL 
activity 
1L11 Bone marrow stroma Stimulates T-cell·dependent development of Ig- 81-83 
producing B-cells; stimulates hematopoiesis 
1L12 B-cells; monocytes Induces the production of IFN gamma by 84-87 
hUman T-helper type 1 cells; synergizes with 
IL2 in induction and proliferation of CTL; 
induces NK-cell lytic activity and proliferation; 
enhances IL3 dependent hematopoiesis in the 
presence of IL 11 and Steel factor 
1L13 T-cells Induces proliferation and differentiation of B- 88-90 
celJs; induces IgE synthesis; regulates 
inflammatory cylokine production and nitric 
oxide production by monocyles 
1L14 T-cells Induces B-cell proliferation 91 
1L15 T-cells Stimulates T-cell proliferation; induces LAK- 92, 93 
cells; interacts with the beta chain of the IL2 
receptor 
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which complex interactions between a number of distinct secondarily secreted 
cytokines and effector cells occur. The interleukins, their sources and biologic 
effects are depicted in Table 1. 
Some of the interleukins may have a direct or indirect inhibitory effect on 
tumor growth (e.g. by activation of T-Iymphocytes or macrophages) and thus may 
be useful for cancer therapy. Immunotherapy of RCC is predominated by 
interleukin-2 (IL2) so we focus on this cytokine in the framework of this review. 
Immunomodulation with IL2 
IL2, first described in 1976, is a glycoprotein Iymphokine mainly produced by 
T lymphocytes of the helper subset (51-53). IL2 induces proliferation of antigen 
stimulated T-cells and, at high concentration, non-specific Iymphokine-activated 
killer (LAK) cells. When appropriately activated, the expansion of T-cells in the 
presence of IL2 can be maintained in culture systems for many weeks or months. 
IL2 is also the predominant cytokine activating NK cells to fully function and IL2-
activated NK cells lyse fresh syngeneic NK-resistant murine and human tumor 
cells (94,95). 
IL2 was also used to grow lymphocytes directly from the peripheral blood or 
spleen. Proliferating lymphocytes could be identified by their ability to lyse fresh 
tumor cells but not fresh normal cells, the socalled LAK phenomenon. These LAK 
cells were initially distinguished from NK cells since they could be derived from 
sites where NK activity was not usually found such as thoracic duct fluid, whereas 
LAK could also kill fresh tumors which were resistant to NK lysis (96-98). It is now 
clear that the majority of cells with LAK activity are large granular lymphocytes 
(LGLs) that do not bear B-cell and T-cell receptors or have functional 
rearrangements of the T-cell receptor genes. Such cells are capable of mediating 
NK activity, LAK activity, antibody-dependent cellular cytotoxicity, and are capable 
of secreting a variety of cytokines (99-101). 
IL2 mediates its effects via specific cell surface receptors. Constitutive 
expression of the IL2 receptor (IL2R) beta chain is observed on macrophages. 
Antibodies blocking IL2 interaction with this chain prevent IL2 induced cytolytic 
maturation of macro phages but not the lytic activity induced by interferon-yo 
Stimulation of macro phages with IL2 causes them to release large quantities of 
TGFp (102,103) an important physiological, antagonistic regulator of tumor 
necrosis factor (TNF) synthesis and action. Multiple other cell types have been 
reported to express the beta chain of the IL2 receptor. Much of the effect of IL2 on 
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other cell types is mediated by the production of other cytokines, subsequent to 
IL2/1L2R interaction. 
IL2 treatment induce,s alteratiop in circulating neutrophil Fc-receptor expressi-
on as well as reduction in chemotactic activity (104,105), which leads to a marked 
increase of the risk of catheter-related infections in IL2 treated patients, which 
requires prophylactic use of antibiotics and/or tunneled catheters (106,107). In 
addition, probably partly due to the induction of IL5, IL2 administration causes an 
increase in circulating eosinophils (108), which are capable of cytolysis of NK 
susceptible targets. 
High dose bolus intravenous IL2 
The initial experience with IL2 in humans was obtained with a regimen of 
intravenous bolus therapy given every 8 hours, which was developed by 
Rosenberg et al. (109). Limited phase I studies demonstrated that the maximum 
tolerated dose (MTD) of this schedule of IL2 was 600,000-720,000 IU/kg, given for 
14-20 doses (110). This regimen of high-dose bolus IL2 has yielded an overall 
response rate in metastatic Ree of 20%, comprising 7% eRs and 13% PRs (110). 
A summary of the literature on the treatment of Ree with high-dose bolus IL2 
alone is shown in Table 2. The overall response rate in these studies was 15% 
(110-114). 
Table 2. High-dose bolus intravenous IL2 alone In metastatic RCC 
IL-2 dose IU/kg x Number of pa- Response Rate Referen-
10.3 (schedule) tients No. (%) ces 
600 (q 8 hrs) 16 0(0) 110 
600 (q 8 hrs) 37 3 (8) 111 
600 (q 8 hrs) 71 12 (17) 112 
720 (q 8 hrs) 149 30 (20) 113 
600-720 (q 8 hrs) 255 16 (14) 114 
Total 528 81 (15) 
High-dose bolus IL2 is associated with considerable toxicity and frequently 
requires intensive care management. The most striking side effects are a capillary 
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leak syndrome and decreased peripheral vascular resistance, leading to interstitial 
and peripheral edema, hypotension and oliguria. In addition, IL2 can cause flu-like 
symptoms as described in the chapter on IFNs. Hence, dose reductions and 
treatment interruptions are necessary in 40-50% of patients. Based on growing 
experience, it has been suggested to reserve high-dose bolus IL2 for patients in 
good condition, with normal cardiac, pulmonary, renal and hepatic function. 
Although concern has been expressed that dose reduction may decrease the 
efficacy of IL2, there is no evidence to suggest that the response rates are indeed 
reduced. Yang et al. (115) performed a randomized trial comparing a high-dose 
bolus IL2 regimen (720,000 IU/kg Lv. every 8 hours), with a low-dose bolus 
schedule (72,000 IU/kg Lv. every 8 hours). The high-dose arm was associated 
with significantly more toxicity. The respective response rates were 15% for the 
low-dose regimen and 20% for the high-dose regimen. There was no difference in 
survival. 
Overall, IL2 induces objective responses in 15-20% of patients with 
metastatic renal cell cancer. Although these response rates are not different from 
the results obtained with IFNs, approximately 1/3 of responders achieve a 
complete response, and moreover responses to IL2 appear to last longer. Some of 
the patients in the early studies are now disease-free for more than 7 years, and 
thus it is conceivable that they have been cured. 
High-dose continuous intravenous IL2 infusion (c.i.v.) 
In an effort to reduce the toxicity related to high-dose bolus IL2, continuous 
intravenous (c.Lv.) infusion has been studied. Some of these studies have 
suggested that c.Lv. IL2 produces greater immunostimulatory effects such as 
greater rebound lymphocytosis, LAK-cell yield, and in vivo immunostimulation 
(116,117). 
West et al. reported that the antitumor effects of c.Lv. IL2 were similar to 
those obtained with high-dose bolus IL2 (118). Toxicity appeared to be somewhat 
less with c.Lv. than with high-dose bolus IL2. With c.Lv. IL2 response rates of 
approximately 15-20% are achieved. The results of the most important trials are 
summarized in Table 3. 
The overall response rates and types of side effects are similar for high-dose 
bolus IL2 and high-dose c.i.v. IL2. The only randomized trial comparing bolus IL2 
to c.Lv. IL2 was conducted by Weiss et al. (124). Forty-eight patients received IL2 
by c.Lv. at a dose of 18-22.5 MIU/m'/day, and 46 patients received 600,000 IU/kg 
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(~ 24 MIU/m') of IL2 every 8 hours by Lv. bolus, Le. a 3-fold difference in total 
dose per course in favor of bolus administration. Infections were more frequent 
Table 3. High-dose c i v IL2 ... 
IL2 dose/day Median LAK cells Number of Response References 
(IU/m' x 10"') given (x 10"10) patients Rate No.(%) 
18 1 51 14 (27) 119 
18 9 47 4 (9) 120 
18-24 15 25 4 (16) 121 
18 7 21 2 (10) 122 
2-6 18 42 14 (33) 123 
18-23 14 48 7 (15) 124 
18 9 46 7 (15) 125 
Total 280 52 (19) 
in patients on c.Lv. IL2, while thrombocytopenia was more frequent in patients on 
bolus IL2. Response rates (15 and 20% respectively) were not significantly 
different. Another conclusion from these studies was that the cumulative MTD of 
IL2 is less for c.Lv. administration than for bolus administration. 
Subcutaneous IL-2 administration 
After subcutaneous (s.c.) administration, many biological response modifiers 
yield sustained blood levels for up to 24 hours. Therefore, some investigators 
explored the s.c. route of administration in order to simplify IL2 therapy and to 
reduce side effects (Table 4). This treatment can be given on an outpatient basis. 
Suter et al. (126) administered IL2 s.c. once daily for 5 days a week for 6 weeks. 
The resulting 20% response rate could not be confirmed by others using 
comparable doses and regimens (127,128). Several studies have combined IL2 
s.c. with IFNa. The reported response rates varied from 12%-25% (127,129,130). 
Clearly, the toxicity of s.c. IL2 is modest in comparison with the intravenous route 
and mostly consist of local inflammation at the injection site and flu-like symptoms. 
In summary, low-dose s.c. IL2 regimens have modest antitumor activity and 
may be an option with greater safety indicated for patients with concomitant 
disease such as cardiovascular abnormalities. However antitumor effects are 
difficult to interpret, because most reported stUdies are small phase I-II trials. 
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Table 4. Subcutaneous IL2 
IL2 dose IFN-a dose Number Overall Reference 
IU/m' x 10-6 U/m' x 10-6 s.c. of response 
(schedule) (schedule) patients (%) 
9-18 
- 46 9 (20) 126 
(5d/w, 4-6w) 
6-30 
- 14 0(0) 128 
(5 d) 
1.8-9 - 14 0(0) 127 
(q12h 5d/w x 
6) 
12 9 42 5 (12) 129 
(4d)15,4w) (2d/w) 
1.5-7.5 2.5-12.5 16 4 (25) 130 
(5d/w) (3d/w) 
5-20 6 51 14 (27) 127 
(3d/w x 6) (1-3d/w x 6) 
5-20 6-9 35 17 (49) 127 
(3d/w x 6) (1-3 d/w x 8) 
plus 5FU 750 
mg/m' 
bolus i.v., 1x15-8 
218 49 (22) 
COMBINATION THERAPY 
The rationale for using combinations of different cytokines is the observation 
that some of these agents such as IL2 and IFN-a have shown synergistic 
antitumor activity against a variety of tumors in preclinical studies (131-132). In 
many weakly or non-immunogenic tumors, the combination of IL2 and IFN-a has 
shown substantial antitumor activity in settings where either agent alone is 
ineffective. Despite the enhancing effect of interferons on class I MHC expression, 
the ability of IFN to enhance the activity of IL2 appears more dependent on NK 
cells, since the synergy between the two cytokines is decreased in NK-deficient 
beige mice and in mice depleted of NK cells (132). Synergy between IL2 and 
interferon in murine models is not restricted to antitumor activity, but pertains to 
toxicity as well (135,136). 
Many clinical trials have been performed to evaluate combinations of IL2 and 
IFN-a. Rosenberg et al. used a high-dose regimen of bolus intravenous IL2 given 
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every 8 hours for 5 days, week 1 and 3, at doses ranging from 3-13.5 MIU/m', 
combined with IFN-a 3 MU/m' intravenously. At the highest dose levels of this 
study response rates of 38% for RCC were observed (137). However this high-
dose schedule of the 2 cytokines appeared to result in increased cardiac-, 
neuropsychiatric-, and hepatic toxicity (143,155). Therefore, subsequent trials 
attempted to decrease toxicity by administering lower dosages. Numerous doses 
and schedules of IL2 and IFN-a have been tested. Intermediate to high dose 
schedules yielded response rates of approximately 16% (112,138-142,144-
148,155). A summary of these trials is given in Table 5. 
Table 5. Combinations of IL2 and IFN·a 
High dose Lv. 
IL2 
Intermediate 
Lv. dose IL2 
Low dose s.c. 
IL2 
Low dose: 
Intermediate dose: 
High dose: 
# patients # studies 
221 5 
183 7 
378 7 
< ZO MIU/c a Y 
20-32 MIU/day 
32-150 MIU/day 
overall response (%) references 
35 (16) 112, 138-
140,155 
32 (17) 141,142,144-
148 
89 (23) 129, 149·154 
Several small studies have focused on outpatient low-dose regimens 
(129,149-154). Although these regimens produce less acute toxicity and are 
therefore easier to administer than high-dose IL2 regimens, most patients 
developed chronic fatigue and a decrease in performance status requiring 
modification or cessation of therapy. 
The Surgery Branch of the National Cancer Institute - USA has reported the 
long-term follow-up evaluation of their initial phase 1111 study (137) and concluded 
that the combined use of IL2 and IFN-a was not indicated based on a lack of 
survival benefit and increased toxicity (155). These findings are in agreement with 
those of a randomized study comparing IL2 + IFN-a versus IL2 alone (112). In this 
trial IL2 alone resulted in a response rate of 17%, while the combination yielded a 
response rate of 11 %. The median survival in the 2 treatment arms was 15,5 
months and 16 months, respectively. 
Presently, an interesting area of research involves the application of chemo-
immunotherapy. Several investigators have added 5-fluorouracil (5-FU) to the 
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combination of IL2 and IFNa and reported response rates varying from 24-49% 
(127,156,157). Whether the addition of 5-FU to IL2/IFN-a represents a benefit will 
have to be addressed in randomized studies. 
The combination of IL2 and IFN-y has also been used in the treatment of 
RCC. Although IFN-y was not able to increase IL2 receptor expression, it did 
increase serum p-2-microglobulin levels (159), IL2 receptors on T-cells, HLA-DR 
expression on NK cells, and Fc receptors on macrophages (160). Increases of 
LAK and NK activity correlated with absence of disease progression (160). IFN-y 
appeared not to worsen IL2 toxicity, but early clincal studies have shown poor 
treatment results, so that the combination of IL2 and IFN-y has not been 
elaborated (159,163). 
Studies on the combination of IL2 with IL4, intended to synergize the 
activation and proliferation of MHC-restricted cytotoxic T-Iymphocytes, failed to 
demonstrate enhancement of immune stimulation or antitumor effect (164-167). 
In tumor bearing animals interesting though unexplained synergistic 
antitumor effects have been demonstrated with the combination of TNFa and IL2 
with a clear dose and schedule dependency (168-170). Optimal results have been 
obtained when TNFa was used at its MTD prior to IL2 administration (169). 
Clinical trials have shown that administration of TNF-a prior to IL2 did not appear 
to increase the toxicity of IL2, while administration of IL2 prior to or concurrent with 
TNF-a appeared to worsen the side effects typical of high-dose IL2 (171-174). 
Although responses were seen, there was no evidence to suggest improved 
efficacy in comparison to IL2 alone. 
In summary combination cytokine therapy failed to improve the clinical 
efficacy of IL2 alone despite promising preclinical data. 
ADOPTIVE CELLULAR IMMUNOTHERAPY 
Adoptive cellular immunotherapy (ACIT) of cancer is a form of passive 
immunization in which immune cells with antitumor properties are transferred to 
the tumor-bearing hos!. These cells may mediate their cytolytic effects either via 
direct contact with and killing of their targets, or indirectly by producing substances 
with tumoricidal or immunomodulatory properties. In ACIT autologous immune 
cells that have been activated and expanded ex vivo are reinfused in the tumor-
bearing host, often in combination with IL2 or other therapeutic agents. The 
effector cells employed for ACIT can be divided in specific (MHC-restricted) or 
non-specific (MHC-unrestricted) immune cells. Lymphokine-activated killer (LAK) 
cells are non-specific, while another population of cytotoxic lymphocytes, tumor-
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infiltrating lymphocytes (TIL) recognize tumor-associated antigens (TAA) in a 
specific MHC-restricted manner. 
ACIT with LAK 
The cultivation of peripheral blood lymphocytes (PBL) in media containing IL2 
(usually at concentrations of 6000 IU/ml) results in the generation of LAK cells. 
LAK is best considered as a functional state of immune cells which may be 
generated from both NK cell and T lymphocyte populations (175). 
After it was demonstrated that large numbers of in vitro activated cells could 
safely be infused in humans, various clinical studies of IL2 and LAK with or without 
IFNa have been performed. These trials used a variety of regimens. The response 
rates ranged from 9-34% (mean 22%) (120,123-125,177-181). These studies are 
summarized in Table 6. 
Table 6 Phase II studies of IL2 and LAK 
IL2 dose Median LAK Number Response References 
IU x 10"" cells given of rate 
(schedule) (x 1Q-lO)/course patients No. (%) 
0.6/kg (q 8w) 10 49 15 (32) 177 
18/m'/d 9 47 4 (9) 120 
18/m'/d 7 46 7 (15) 125 
18/m'/d 6.5 102 17 (18) 178 
18-23/m'/d 14 48 7 (15) 124 
16/m'/d 5.6 23 6 (26) 179 
2-6/m'/d 18 42 14 (33) 123 
8-16/m'/d 11 
+ IFN-a 12 MU/m' 
40 8 (20) 180 
3x1w 
18/m'/d 9.6 68 23 (34) 181 
+ IFN-a 5 MU/m'/d 
Total 465 101 (22) 
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In general, the addition of LAK cell infusion to high-dose IL2 therapy has not 
been shown to be superior over single agent high-dose IL2. Three randomized 
trials have been carried out to determine whether the addition of LAK offers a 
therapeutic benefit, but none showed a higher response rate or longer survival 
(111,177,182). The reasons for this may be various. LAK cells were shown not to 
localize selectively in tumors (183,187). In addition, the therapeutic effect of LAK is 
probably related to the cytotoxic effects of tumor specific T -Iymfocytes at the site 
of the tumor (184-188). Immunophenotypic analysis of cellular infiltrates of 
regressing melanoma lesions revealed the presence of CD3· but not CD3' CD16· 
infiltrating cells, suggesting that T-Iymphocytes rather than NK cells were 
responsible for the antitumor effect (185,186). Taken together, these findings 
indicate that direct (IL2 mediated) or indirect (through release of secondary 
cytokines) activation of tumor-specific T-cells form the basis of adoptive cellular 
immunotherapy of cancer. 
ACIT with TIL 
Another population of cytolytic lymphocytes, that can be used as effector 
cells in combination with IL2, are tumor-infiltrating lymphocytes (TIL). These 
immune cells possess potent antitumor activity and are derived from lymphocytes 
which have infiltrated tumor lesions. In contrast to LAK, murine and human TIL 
demonstrate cytolytic specificity only against the tumor from which they are 
derived or against closely related tumors (189,190). In murine systems TILs are 
50-100 times more potent than LAK in their cytolytic capacity (189). Murine TILs 
are predominantly CD3· CD4' CDS·, while human TILs are phenotypically more 
heterogenous, which may reflect the difficulties encountered in obtaining true TIL 
from human tumors, which by definition also contain PBC. This heterogeneity may 
be the reason that in vitro cytotoxicity of TIL is not a good predictor for their ability 
to cause tumor regression in vivo (191). An exception to this rule are TILs derived 
from melanomas, which manifest MHC-restricted interactions with tumor targets in 
at least 50% samples. TILs with specific lytic activity for autologous tumor but not 
for normal autologous tissues or for allogeneic tumor can be derived from 
approximately one-third of all patients with melanoma (191,192). For this reason, 
clinical trials of TILs in humans have concentrated on melanoma and response 
rates of 20-30% have been reported (125,193-195). In RCC the experience with 
TIL is very limited and antitumor responses are rare (193,195-197). The same 
holds true for small studies with TILs and IL2 in combination with IL4 or IFNa 
(198-200). 
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FUTURE PERSPECTIVES 
From the above reviewed literature it becomes clear that no standard 
immunotherapy of RCC can be recommended, since the cytokines and effector 
cells mentioned do not offer clearcut benefit for larger groups of patients. 
However, it is for the first time in the long history of immunotherapy that treatment 
strategies can be rationally designed on the basis of our increased knowledge of 
the function of the immune system and its interaction with tumor target cells, 
whereas at the same time these strategies can be materialized with the help of 
recently developed methods of molecular engineering. 
What is clearly needed in the clinical arena is the development of efficient 
effector cells which are tumor selective. Although T-Iymphocytes are equipped with 
T-cell receptors which can recognize and bind TAA, this is clinically futile since 
tumor cells often do not express their T AA adequately in association with MHC 
molecules, which makes recognition by the T-cell receptor impossible. The CD3 
antigen is an activation molecule physically associated with the T-cell receptor. 
Binding of the CD3 antigen to TAA leads to activation of the T-cell, followed by 
Iymphokine production and cytolytic activity (211). This approach of targeting 
immune cells to tumor cells has been elaborated in preclinical and clinical studies. 
ACIT with T-Iymphocytes retargeted with bispecific monoclonal antibodies 
Bispecific monoclonal antibodies (bs-MAb) are hybrid antibodies constructed 
from two parent MAbs: one specific for the immune effector cell and the other 
specific for a T AA on the target cell. Bs-MAb-mediated cross-linking of the effector 
T cell to the tumor target cell results in activation of the lymphocyte leading to 
lysis of the tumor cell (201-205,211). Bs-MAbs are usually constructed by somatic 
hybridization of 2 mouse hybridomas. Several bs-MAbs have been developed with 
specificity against RCC, ovarian cancer and breast cancer (2·11-116). 
One of the first clinical trials testing this concept was in ovarian cancer with a 
bs-MAb against the overexpressed folate-binding protein on the tumor cells and 
against the activation antigen CD3 (206-208). A clinical phase I-II study was 
carried out in ovarian cancer patients with recurrent disease confined to the 
peritoneal cavity. Patients were treated with daily intraperitoneal infusions of 
autologous in vitro expanded T -lymphocytes retargeted with the bs-MAb. Infusions 
were given with low-dose IL2. The overall intraperitoneal response rate was 27% 
(209). The development of neutralizing human anti-mouse antibody (HAMA) was 
observed in all patients after approximately 2-3 weeks from the start of treatment 
(210). 
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The use of mouse monoclonal antibodies has several disadvantages such as 
a short serum half-life, limited potential to trigger human effector cell functions and 
HAMA response (217-219). These problems have led to the construction of 
"humanized" antibodies, which have been shown to be less immunogenic than 
their murine counter parts (220-223). 
However, despite this improvement in antibody technology, the use of bs-
MAbs can still be hampered by the inaccessibility of solid tumor to antibody 
penetration. In addition, bs-MAb redirected T-cells retain the antibody for limited 
periods of 48-69 hours due to dissociation from the T-cell surface. It has also been 
demonstrated that bs-MAb redirected T-cells lose their signal transducing and lytic 
capacity following target cell recognition (209,224). To circumvent the limitations 
associated with bs-MAb, a new approach has been adopted in which T-cells are 
"gene-grafted" with a permanent antibody dictated specificity. 
Gene modified chimeric T-ceJl receptor 
By the construction of a chimeric immunoglobulin T-cell receptor complex (Ig-
TCR), tumor selectivity of T lymphocytes may be obtained. To be effective such T 
lymphocytes would require stable expression of the engineered Ig-TCR receptor at 
the lymphocyte surface and its functional association with the CD3 signal-
transducing element. This has been achieved by the introduction and expression 
of chimeric IglTCR genes, in which the variable (V) gene segments of the TCRu 
and TCR,B chains are replaced by the variable gene segments of the heavy and 
light chain of an Ig with known specificity (225-230). Retroviral gene transfer is 
employed to transduce the chimeric receptor into activated T lymphocytes. The 
transduced T lymphocytes stably express the receptor for >4 months of in vitro 
culture (230). Stimulation of the chimeric receptor results in T cell activation, 
cytokine production and lysis of target cells (228-230). 
In contrast to BsMAbs redirected lymphocytes, lymphocytes transduced with 
chimeric Ig-TCR genes show recycling of the cytolytic process (230). An essential 
feature of Ig-TCR targeted lymphocytes is their ability to recognize tumor-
associated antigens in a MHC-unrestricted manner. 
Cytokine gene modified tumor ceJls 
Cytokines provide costimulatory signals important for T lymphocyte 
activation. Because most cytokines have a short serum half-life, local delivery may 
be attractive and in addition potentially less toxic. One loco regional approach is to 
introduce genes encoding for cytokines into tumor cells sothat the cytokine is 
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continuously secreted by the tumor cell, resulting in effective cytokine 
concentrations in the vicinity of tumor cells and tumor antigens, but not elsewhere 
in the body. Many cytokine genes have been introduced into tumor cells with 
varying effects on both tumorigenicity and immunogenicity. This new tumor 
vaccine approach has been best developed in murine models (231-235). Pilot 
studies of cytokine transfer by vaccination with engineered tumor cells in patients 
have started (236,237). However, adequate T AA expression and recognition 
remains a problem (238). 
Cytoklne gene modified effector cells 
Although it has been relatively easy to express cytokine genes in tumors 
cells, this is not the case in lymphocytes, where it is difficult to achieve constant 
high levels of cytokine production, which is probably due to regulatory 
mechanisms (239). Moreover, large numbers of T cells are required for adoptive 
therapy, and consequently, a high transduction efficiency is needed to enable the 
grow1h of adequate numbers of gene modified cells. Recently, gene therapy of 
RCC has focused on TNF gene transfer into TIL (240). 
There are other possibilities for the introduction of cytokine genes into TIL. 
For example, TIL transduced with the gene for the IL2 receptor may increase their 
sensitivity to IL2. The introduction of IFN-a or IFN-y genes into TIL could cause 
direct antiproJiferative effects and upregulation of MHC antigens, increasing the 
immunogenicity of the tumor. However, it should be remembered that the 
existence of true TIL in RCC is still controversial. 
Tumor vaccines 
Active specific immunotherapy with vaccines constructed of T AA is 
conceptually an attractive approach to treatment and possibly to prevention of 
cancer. The rationale is that such vaccines may be able to stimulate the immune 
system more vigorously and activate silent precursor lymphocytes with tumor 
specificity. However, in most types of human cancer, there is little evidence that 
primary or metastatic tumors induce immunity in patients. Occasionally, melanoma 
patients were found to have demonstrable tumor specific antibodies and cytotoxic 
T lymphocytes (241-243). The problem with human tumors appears to be poor 
immunogenicity of relevant antigens which permits tumor cells to escape the 
immune attack and active inhibition of the host immune response by the tumor 
cells (244). Thus far, a number of antigens have been identified as targets for 
recognition by cytotoxic lymphocytes, mostly in melanoma, but also in other 
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tumors types (245-251). Vaccination studies with immunogenic peptides in humans 
have recently started (252,253). 
It can 'be concluded that the past 15 years have witnessed revolutionary 
developments in tumorimmunology and experimental immunotherapy. Firstly, our 
understanding of the communication network between immune cells has 
significantly increased. Secondly, the availability of recombinant DNA techniques 
has enabled the isolation and production of a whole series of interleukins which 
can be studied in preclinical and clinical models. Finally, new and refined methods 
of tumor specific targeted immunotherapy are on the brink of clinical application. 
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SUMMARY 
Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a 
study of continuous daily intrapleural infusion of interleukin-2 (lL2) for 14 days, 
repeated every 4 weeks. IL2 was administered according to a groupwise dose 
escalation schedule (Group A: 3 x 10', B: 3 x 10', C: 3 x 10', 0: 6 x 10', E: 18 x 
10', and F: 36 x 10' IU/day). Each group consisted of at least 3 patients. 
Intrapleural administration of IL2 was associated with acceptable toxicity. All 
patients were treated on an outpatient basis except for the patients at dose levels 
E and F. Dose limiting toxicity was observed at level F: 36 x 10' IU daily and 
consisted of catheter infection, fever, and flu-like symptoms. 
Intrapleural IL2 levels were high (> 20,000 IU/ml) at levels E and F, while 
serum levels in most patients were not or barely detectable «3 - 30 IU/ml). 
Intrapleural IL2 levels were up to 6000 fold higher than systemic levels. 
Intrapleural tumour necrosis factor-alpha (TN Fa) levels varied greatly and did not 
correlate with IL2 dosage. Intrapleural mononuclear cells (MNC) displayed IL2-
induced Iymphokine-activated killer (LAK) activity in all patients. 
Two patients were not evaluable for response due to catheter-related problems 
which precluded the delivery of IL2. Partial response (PR) occurred in 4 of 21 
evaluable patients (19%; 95% confidence interval 5 - 42%) with a median time to 
progression of 12 months (range 5 - 37). Stable disease (SO) occurred in 7 
patients with a median time to progression of 5 months (range 2 - 7). There were 
no complete responses (CRs). The median overall survival was 15.6 months 
(range 3.0 - 43). No relationship between the dose of IL2 and response rate was 
observed. 
We conclude that IL2 given intrapleurally is accompanied with acceptable 
toxicity and has antitumour activity against mesothelioma. In view of the refractory 
nature of the disease IL2 may be a treatment option for mesothelioma. A formal 
phase II study is warranted. Based on the observed toxicity, the lack of dose 
response relationship, and the immuno-modulatory effects seen at relative low 
dose IL2, the recommended dose for a phase II study is 3 x 10' IU/day using the 
present treatment schedule. 
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INTRODUCTION 
Untreated patients with pleural mesothelioma have a median survival of 9 
months and may survive just as long as treated patients (Hillerdal, 1983; Law, et 
al. 1984). Current treatment methods do not appear to improve survival (Alberts, 
et al. 1988). Therefore, new treatment modalities should be investigated. 
In intraperitoneal tumour models it has been demonstrated that intracavitary 
administration of interleukin-2 (IL2) can induce very high numbers of Iymphokine 
activated killer cells (LAK) in the peritoneal exudate (Eggermont, et al. 1988 & 
1989). Consequently, intrapleural administration of IL2 for the treatment of pleural 
mesothelioma appears to be a reasonable therapeutic approach, particularly since 
mesothelioma tends to be confined to the pleural cavity for the most part of the 
course of the disease. Yasumoto et al (Yasumoto, et al. 1987) reported the 
complete clearance of malignant cells after intrapleural instillations of IL2 in 
patients with pleurisy due to lung cancer. Astoul et al. (Astoul, 1993) reported 
objective responses in mesothelioma patients treated with continuous intrapleural 
IL2 instillation. 
Based on these observations, we performed a phase I-II study with intrapleural 
IL2 in patients with pleural mesothelioma stage I-IIA, classified according to the 
Butchart staging system (Butchart, et al. 1976). 
PATIENTS AND METHODS 
Patients 
Staging and diagnosis of mesothelioma was based on computed tomographic 
(CT) scan of the chest, thoracoscopic findings, and histologic examination of 
biopsy samples. 
All biopsies were reviewed by our institution's pathologist. The staining 
techniques used included haematoxylin and eosin, special stains for reticulin and 
mucins (such as mucicarmine, periodic acid-Schiff after diastase, and the alcian 
blue stain with and without prior digestion with hyaluronidase), and the immuno-
histochemistry stain for CEA, keratin, CAM-5.2, and an epithelial membrane 
antigen MOC-31. 
According to Butcharts' staging system (Butchart, et al. 1976) stage I is defined 
as tumour confined within the capsule of the parietal pleura, i.e. involving only 
ipsilateral pleura, lung , diaphragm, and external surface of the pericardium within 
the pleural reflection. Stage IIA is defined as mesothelioma invading chest wall or 
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mediastinal tissues with or without lymph node involvement ipsilaterally inside the 
chest. 
Eligibility criteria required histologically confirmed pleural mesothelioma stage I-
liA, sufficient pleural effusion to insert an intrapleural catheter, no signs of 
loculation on the CT scan, no prior chemo-, radio-, or immunotherapy, age < 76 
years, Karnofsky performance status ;" 80, no cardiovascular disease, a white 
blood cell count;" 40001ml, a platelet count;" 100,000Iml, haematocrit ;" 30%, 
serum bilirubin and creatinine levels within the institution's normal range, no active 
infection, no use of corticosteroids, and obtained informed consent. 
Treatment 
One to two weeks prior to the first administration of IL2 a port-a-cath system 
was surgically inserted under general anaesthesia. The correct intrapleural 
position of the catheter was examined radiographically and a Technetium 99m 
colloid scan was made to evaluate the distribution of pleural fluid throughout the 
pleural cavity. 
Recombinant human interleukin-2 (IL2) (Chiron B.V., Amsterdam, The 
Netherlands) was administered as a continuous intrapleural infusion at a dose 
according to a groupwise dose escalation schedule (Group A: 3 x 104 , B: 3 x 105 , 
C: 3 x 10', 0: 6 x 10', E: 18 x 10', and F: 36 x 10' IU/day) for 14 days, repeated 
every 4 weeks. After 2 cycles, response to treatment was evaluated. Each group 
consisted of at least 3 patients. Patients with stable disease or response could 
receive up to a maximum of 6 cycles. No intrapatient dose escalation was 
performed. 
All patients were seen weekly at the outpatient clinic. Masks and sterile gloves 
were used for all dressing changes, and dressings were changed only by trained 
nursing personnel. 
Response and toxicity 
Response was evaluated after every 2 treatment cycles using CT -scan of the 
chest. Tumour response and toxicity were assessed according to the criteria of the 
World Health Organization (WHO) (WHO handbook, 1979). In case of measurable 
disease, complete response (CR) was defined as the disappearance of all known 
disease for at least 4 weeks; partial response (PR) as a decrease > 50% in 
tumour size for at least 4 weeks; stable disease (SO) as a decrease of < 50% in 
tumour size. Progressive disease (PO) was defined as an increase> 25% in the 
diameter of any lesion or the appearance of a new lesion. 
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In case of unmeasurable but evaluable disease a CR was defined as the 
complete disappearance of all known disease for at least 4 weeks; a PR as an 
estimated decrease in tumour size of ;" 50% for at least 4 weeks; SD as an 
estimated decrease of less than 50%, and lesions with estimated increase of less 
than 25%. PD was defined as the appearance of any new lesion not previously 
identified or estimated increase of 25% or more in existent lesions. 
Pleural effusion was not considered an adequate parameter of response or 
progression by itself. It would not detract from a PR or SD. However, if remaining 
present, it would reduce a CR to a PRo 
Time to progression and survival were calculated from the start of treatment to 
the date of progressive disease or death, respectively, according to the Kaplan 
and Meier method (Kaplan, 1958). 
Toxicity was recorded and analysed using the WHO grading system. For 
toxicities not included in the WHO guidelines, a grading system was used ranging 
from mild (grade 1) to life-threatening (grade 4). 
Immunomonitorlng 
All samples were taken at the same time of the day (preferably in the morning) 
since a circadian rhythm has been described for a number of functions. 
Mononuclear cells (MNC), serum samples and pleural fluid (if present) were 
collected weekly during each course and cryopreserved until tested. 
Immunophenotyping 
MNC were isolated from heparinized pleural and peripheral blood samples by 
density centrifugation (Ficoll-Isopaque). MNC were washed, resuspended at a 
concentration of 1 x 10'/ml in phosphate buffered saline (PBS) + 1 % bovine serum 
albumin (BSA) and stained with fluorescein isothiocyanate (FITC) or phycoerythrin 
(PE) conjugated monoclonal antibodies (mAbs). 
The following mAbs were used: anti-Leu4/FITC (CD3); anti-Leu3a/FITC (CD4); 
anti-Leu2a/PE (CD8); anti-Leu 11c/PE (CD16); anti-Leu12/FITC (CD19) and anti-
Leu19/PE (CD56). All mAbs were purchased from Becton and Dickinson 
Immunocytometry Systems (BDIS, San Jose, CA, USA). 
After incubation with the mAb for 30 minutes at DoC, MNC were fixed in PBS 
containing 1 % paraformaldehyde, stored at 4°C and flow cytometry was performed 
within 24 h using a FACScan (BDIS). 
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Cytotoxicity assays 
Cytotoxic activity of MNC was determined in a standard 3-h 5'Cr release assay. 
Briefly, lymphocytes were seeded in triplicate in 96-well, round-bottomed microtiter 
plates. Target cells labelled with 5'Cr were added and at the end of the incubation 
period (37°C and 5% CO,), supernatants were collected, and 5'Cr release was 
measured. Target cells were the NK-sensitive K562 chronic myelogenous 
leukemia cell line and the NK-resistant, LAK sensitive Oaudi Burkitt lymphoma cell 
line. 
Determination of cytokine levels 
In the patients where pleural fluid could easily be obtained, this was done prior 
to and during treatment with IL2. At the same time blood samples were taken in 
order to compare intrapleural IL2 and tumour necrosis factor-alpha (TNFa) levels 
with simultaneous blood IL2 and TNFa levels. 
IL2 was measured with a double antibody radio-immunoassay using a 
polyclonal antiserum (IRE-Medgenix, Fleurus, Belgium). The detection limit is 
about 0.5 U/ml (3.0 IU/ml). The interassay coefficient of variation at a level of 10' 
U/ml is 6.8%. One unit in this assay corresponds with 6 IU. 
TNFa was measured with a coated tube immuno-radiometric assay (IRE-
Medgenix, Fleurus, Belgium). The detection limit is 5 ng/l and the interassay 
coefficient of variation at a level of 131 ng/l is 7.2%. 
RESULTS 
Toxicity profile and tumour response 
Twenty-three male patients with epithelial type malignant pleural mesothelioma 
stage I or IIA, without prior treatment, were eligible for the study. Most of them 
were shipyard workers with a history of asbestos exposure. Their median age was 
57 (range 47-71) and their median Karnofsky performance status 100 (range 90-
100). 
Twenty-one patients were evaluable for toxicity and tumour response (Tables I 
and II). Two patients were inevaluable for toxicity and response due to catheter-
related problems which prevented the delivery of any IL2. At least one treatment 
cycle of 14 days was received by 5 patients at 3 x 10' IU/day, 2 patients at 3 x 105 
IU/day, 3 patients at 3 x 10' IU/day, 3 patients at 6 x 10' IU/day, 3 patients at 18 x 
10' IU/day, and 1 patient at 36 x 10' IU/day. Five patients were started at the 
highest dose level but only one patient was able to receive one cycle. The other 4 
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patients were unable to complete one treatment cycle because of catheter-related 
infections which required catheter removal before the completion of the first cycle. 
After 5 patient entries at this dose level the study was stopped. Hence, this dose 
was not tolerated by 4 of the 5 patients (Table I). 
In general, IL2-mediated toxicity was mild to moderate, except at the highest 
dose level. At this level, in addition to the catheter-related infections, fever and flu-
like symptoms were dose limiting. The systemic side effects such as fever and 
skin toxicity corresponded with serum IL2 levels, which reached 30 IU/ml in group 
F. All patients received their treatment in an outpatient setting except for the last 5 
patients who were treated at level F: 36 x 10' IU/day. No serious systemic adverse 
effects such as hypotension, cardiovascular disturbances, pulmonary oedema, 
liver and renal dysfunction were observed, with the exception of one patient in 
group F, in whom grade 3 nephrotoxicity was noted. Mild leucocytosis (10,000-
12,000 cells/ml) and eosinophilia (2000-3500 cells/ml) in the peripheral blood were 
seen in most patients at all dose levels. 
Treatment-related complications were infection of the port-a-cath systems in 7 
patients, 4 of whom were treated at the highest dose level in group F. 
Clinical signs of empyema were noted in 5 of the 7 patients with a port-a cath 
infection. These 5 required removal of the port-a-cath system in combination with 
drainage by thoracotomy. As can be seen in Table I a variety of micro-organisms 
were cultured from pleural samples and removed port-a-cath systems of these 
patients which suggests a secondary bacterial infection in necrotic tissue. 
Patients received from less than one up to 6 complete treatment cycles. There 
were no complete responses. Partial response occurred in 4 of 21 evaluable 
patients (19%; 95% confidence interval 5 - 42%) with a median time to 
progression of 12 months (range 5 - 37). Stable disease occurred in 7 patients, 
the median time to progression was 5 months (range 2 - 7). Six patients had 
progressive disease. The median overall survival was 15.6 months (range 3.0 -
43). Responses occurred at different dose levels, therefore no dose-response 
relationship can be established (Table II). Figure 1 shows a representative 
example of a tumour response. 
Three of the 4 PRs with a long lasting response underwent thoracotomy. In 
patients 10 and 8, an infected port-a-cath with concomitant empyema was noted 
after 1 and 4 cycles, respectively (Table II). 
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Table I. Toxicity in relation to intrapleural IL2 in 21 evaluable patients (WHO 
grade;;" 2) 
Dose level 3x10' 3x10' 3x10' 6x10' 18x10' 36x10' 
(IU) 
Group A B C D E F 
Patients 5 2 3 3 3 5 
# cycles 14 8 11 10 7 4 
Fever> - 1* 1 1 2 5 
38"C 
Flu like - 1 1 - - 4 
Myalgia - 1 - 1 - 2 
Arthralgia - 1 - 1 - -
Diarrhea 1 - - - - 1 
Non- 1 1 2 1 1 1 
productive 
cough 
Dyspnea 1 - 1 2 2 -
Arrhythmia - - - 1 - -
Anorexia - - - 1 1 1 
Skin - - - - - 3 
Creatinine - - - - - 1 
elevation 
Leucocytosis 1 1 1 3 3 3 
(>10,000 
cells/ml) 
Eosinophilia 
- 1 2 2 1 1 
(>2,000 
cells/ml 
Infection - 1 1 - 1 4 
Bacterial 
- 1 1 - 1 4 
culture s.aureus s.aureus streptococcus s.epidermidis 
(3) 
eubacterium 
(1 ) 
Thoracotomy - 1 2 - 1 1 
due to 
empyema 
* number of patients per dose level experiencing toxicity 
53 
Chapter 2 
Table II. Clinical data and response to therapy in 21 evaluable patients with 
pleural mesothelioma treated with intrapleural IL2 
* 
Pat. nr. IL2 (IU/d) Age # Cycles Response Progression Overall 
Free Su rvival Survival 
(months) (months) 
1 3x10' 51 4 PR 5 15 
2 3x10' 47 1 SO 4 8 
3 3x10' 50 0 NE' - 7.5 
4 3x10' 63 5 SO 5 9 
5 3x10' 71 2 PO 1 5 
6 3x10' 57 2 PO 1 19 
7 3x10' 49 0 NE' - 10 
8 3x10' 54 6 PR 17 23 
9 3x10' 52 2 PO 1 10 
10 3x10' 59 1 PR 12 31 
11 3x10' 62 4 SO 3 6 
12 3x10' 51 6 PR 37 43 
13 3x10' 63 6 SO 5,5 28 
14 3x10' 64 2 PO 1 16 
15 3x10' 62 2 PO 1 17 
16 18x10' 69 2 SO 7 10 
17 18x10' 62 3 SD 2 18 
18 18x10' 59 2 PD 2 3 
19 36x10' 48 2xY> SD 6 10 
20 36x10' 49 Y> SD -* 9 
21 36x10' 55 1 SD 5 26 
22 36x10' 54 Y> SD -* 16 
23 36x10' 59 3/4 SD -* 26+ 
Pts 20 - 22 - 23 received additional cisplatin and etoposide, thus appropriate 
PFS cannot be determined. 
Pts 3 and 7 did not receive IL2 intrapleurally due to catheter related problems 
and were thus inevaluable. 
In both these patients massive tumour necrosis was found. Bacterial cultures 
revealed S.aureus in both cases. In patient 8, whose near-complete response 
lasted 17 months, a fenestration of the thoracic wall had to be performed in order 
to prevent recurrent empyema. In a second stage, the pleural cavity, which was 
macroscopically still free of tumour, was closed by a pedicled omentoplasty. The 
patient did very well for 17 months, until mesothelioma developed in the 
contralateral pleural cavity. In patient 12, a fistula developed after 5 cycles and 
required ribresection. Thoracotomy showed a completely necrotized pleural 
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mesothelioma. Bacterial cultures were negative. One of the multiple pleural 
biopsies contained mesothelioma cells. Two patients with SD, patients 19 and 16, 
showed clinical signs of empyema after 1 and 2 cycles, respectively. A 
thoracotomy was performed and extensive necrosis was found in the remaining 
tumour. Bacterial culture revealed streptococcus in one and was negative in the 
other patient. In these 3 patients (12, 16 and 19) CT-scans showed no tumour 
regression whereas histologic examination revealed extensive tumour necrosis. 
These findings underscore the difficulties in the clinical evaluation of response in 
mesothelioma. 
Immunomonitoring 
After intrapleural administration of IL2 a mild increase of CD3-56', CD3'56', 
and CD3-16' lymphocytes was observed in pleural effusion as well as in peripheral 
blood. All other T-Iymphocyte subsets remained at normal levels. 
At dose levels A through D cytotoxicity assays showed a significant induction 
of LAK activity by pleural effusion derived MNC but not by peripheral blood MNC. 
At dose levels E and F, LAK activity was induced in MNC from both sites. Of note, 
no differences in LAK activity were seen between responders and nonresponders. 
Determination of cytokine levels 
Intrapleural as well as serum IL2 levels were determined. Intrapleural levels 
were very high and correlated with the administered dose of IL2. Intrapleural levels 
varied from 6 - 110 IU/ml in group A to as high as 66,000 - 192,000 IU/ml in group 
F. Serum IL2 levels became measurable only in groups E and F, and varied in the 
8 patients treated at those levels from < 3 IU/ml to 30 IU/ml. Intrapleural IL2 levels 
were up to 6000 times higher than serum levels. 
Intrapleural TNFa levels varied from 50 - 125 pg/ml in group A to 235 - 405 
pg/ml in group F. However, no clear relationship between TN Fa and IL2 levels 
was observed as TN Fa levels in groups B-E varied from 292 - 1141 pg/ml. 
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Figure 1. 
Partial response of pleural mesothelioma (evaluable disease) and a mediastinal 
lymph node (measurable disease) metastasis in the left hemithorax. Top: 
pretreatment CT-scan. Boltom: after 2 cycles of IL2. 
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DISCUSSION 
In this phase I-II study on the toxicity and efficacy of intrapleural 
administration of IL2 in patients with pleural mesothelioma we observed antitumour 
activity with acceptable toxicity. The response rate of 19% in 21 patients is of 
interest as mesothelioma is known to be refractory to treatment. 
The basis of this study was the observation of a dose-response relationship in 
experimental tumour models (Rosenberg. et al. 1987 & 1989; Ettinghausen 1986; 
Eggermont. et al. 1988). Systemic high dose IL2 therapy is associated with severe 
toxicity. which may prohibit the possibility to apply doses with optimal antitumour 
effects (Herberman. 1989). Intrapleural administration of IL2 is therefore a logical 
approach as it can be expected that very high local levels of IL2 can be delivered 
without severe systemic adverse effects. We have demonstrated that high 
intrapleural levels IL2 are associated with mild to moderate toxicity. except in 
those patients treated at the highest dose level F with 36 x 106 IU/day. All patients 
in groups A to E were treated on an outpatient basis. 
Intrapleural administration of various biological response modifiers may have 
significant antitumour effects against intrapleural malignant disease. Uchida et al. 
(Uchida. et al. 1984) reported that intrapleural instillation with the biologic 
response modifier OK-432 significantly increased autologous tumour killing by 
tumour associated large granular lymphocytes. The intrapleural instillation of 
natural beta-interferon was reported to be effective against malignant pleural 
effusions by Rosso et al. (Rosso. et al. 1988). Recently. Markowitz et al. 
(Markowitz. et al. 1992). reported on the efficacy of intracavitary administration of 
IFN-a. Boutin et al. (Boutin. et al. 1991) reported 4 eRs and 2 PRs after weekly 
intrapleural administration of gamma-interferon in 22 patients with mesothelioma. 
also underscoring the therapeutic potential of locoregional cytokine therapy. 
Antitumour effects after intrapleural administration of TNFa have been 
reported by Karck et al (Karck. et al. 1990). Intrapleural administration up to 200 
microgram/m' weekly in 7 patients with malignant pleural effusion led to complete 
disappearance of tumour in 3 patients without side effects. The same group 
reported that in patients with ovarian cancer and recurrent ascites intraperitoneal 
administration of TNFa resulted in the disappearance of ascites in 7 of 9 patients. 
Yasumoto et al. (Yasumoto. et al. 1987). demonstrated that low intrapleural 
doses of IL2 were sufficient to induce Iymphokine-activated killer activity in the 
pleural exudate and to reduce malignant pleural effusions. Manning et al. 
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(Manning, et al. 1989) have shown that these activated lymphocytes were able to 
kill NK cell-resistant human mesothelioma cells. 
Astoul et al (Astoul, et al. 1993) reported a relatively high response rate (7/15 
patients) in mesothelioma patients who were treated with intrapleural IL2 in a dose 
escalation study. The preponderance of responses was observed in stage I 
disease. 
We made similar observations in our study. Significant LAK-activity was 
displayed by MNC collected from the pleural effusions after intrapleural 
administration of IL2. No LAK-activity was displayed by the peripheral MNC, 
except at the highest 2 dose levels in groups E and F. However, LAK activity and 
response did not correspond with IL2 dose level, intrapleural IL2 level or 
intrapleural TNFa level. 
Immunophenotyping of intrapleural and peripheral MNC showed some 
changes after intrapleural administration of IL2. In this study, the dose of IL2 did 
not correlate with response, and none of the parameters investigated by 
immunophenotyping, cytotoxicity assays and determination of cytokine levels 
corresponded with the outcome of treatment. 
Dosages of IL2 in this study were tolerable up to and including level E: 18 x 
10' IU/day. However, at level F: 36 x 10' IU/day, catheter-related infection was the 
most pronounced and dose-limiting side effect. Others have reported neutrophil 
dysfunction during IL2 administration including decreased chemotaxis and Fc 
receptor expression (Klempner, et al. 1990; Jablons, et al. 1990; Murphy, et al. 
1988). High dose IL2 increased the risk of bacteremia significantly, which led to a 
reduction of catheter indwelling time (Richards, et al. 1991). These facts may 
explain the high incidence of catheter-related infections in our patients, particularly 
in group F, and after repeated administration of IL2 at the lower doses. 
It remains uncertain if and to what extent these infections have played a role 
in the induction of an antitumour response, as 3 of the 4 responders developed an 
empyema, but 2 of the 5 patients with an empyema had no response. In addition, 
IL2 by itself induced high intrapleural levels of TNFa in the majority of the patients 
treated. 
We conclude that intrapleural administration of cytokines should be explored 
further as a new mode of treatment for pleural mesothelioma. IL2 given 
intrapleurally appears to have antitumour activity against mesothelioma. We are 
aware of the difficulty recommending a daily dose of IL2 because of the small 
numbers of patients in each group and the frequent occurence of empyema, but 
given the facts that a) no correlation was found by us and by others between IL2 
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dose and antitumour response, b) low intrapleural IL2 doses are sufficient to 
induce LAK-activity by MNC which can kill NK cell-resistant human mesothelioma 
cells, and c) mild toxicity was seen below 6 x 10' IU of IL2, we suggest a daily 
dose of 3 x 10' IU of IL2 for a phase II study. 
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SUMMARY 
Background: A clinical study to investigate the effects of prolonged continuous 
infusion of interleukin-2 (IL-2) via the hepatic artery in patients with unresectable 
liver metastases of coloreclal cancer was performed. 
Patients and methods: Of fourteen selected patients 9 received interleukin-2. 
Five patients had to be excluded due to anomalous arterial anatomy. IL-2 was 
administered by continuous arterial infusion in 2 cycles of 12 days at 3 week 
intervals. Intrapatient dose escalation was applied. A minimum of 3 evaluable 
courses were applied. Doses ranged from 1.5 - 12 x 10' IU/m'/day. 
Results: In the patients receiving the lowest 2 dose levels of IL-2 very little 
toxicity was seen. At the dose of 6 x 10' IU/m'/day however considerable hepatic 
toxicity but relatively little systemic toxicity was observed. The maximal tolerated 
dose (MTD) of IL-2 was 6-12 x 10' IU/m2/day. Thrombosis of the hepatic artery 
was observed in 2 of 5 patients treated at the lower IL-2 dose levels and in 3 of 4 
patients at the highest IL-2 dose levels. These thromboembolic complications are 
possibly due to endothelial damage by the prolonged infusion of high doses of IL-
2. The rate of this complication was so high that the study was stopped after 9 
patients. Eight patients had progressive disease, one patient had stable disease 
for a period of 6 months. 
Conclusions: This study demonstrates that small caliber arteries like the 
gastroduodenal artery are not suitable for prolonged infusion of IL-2. We do not 
recommend this approach for the regional treatment of liver metastases with IL-2. 
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INTRODUCTION 
The liver is a major site of metastatic spread of primary colorectal cancer; in as 
many as 30% of the patients it is also the sole site of initial tumor recurrence [1]. 
In the majority (75%) of these patients the metastases are not resectable and 
most patients can be considered candidates for loco regional therapies as the 
effect of systemic chemotherapy results in relatively low response rates with 
minimal effect on survival [2]. Unfortunately, although improved response rates 
with hepatic arterial infusion chemotherapy have been reported, convincing 
evidence of improved survival with these techniques is also lacking [3, 4, 5]. 
Therefore the search for new drugs and new treatment modalities is warranted. 
Many clinical stUdies on the effects of the systemic administration of the cytokine 
interleukin-2 (IL-2) have been performed, but relatively few studies on regional 
administration of IL-2 have been published. The most favorable results of IL-2 
based immunotherapy have been achieved in patients with renal cell cancer, 
melanoma and Non-Hodgkin's Lymphoma. Results obtained in other malignancies 
have been disappointing, but incidental long lasting remissions in patients with 
colorectal cancer have been observed [6]. Although no clear dose-response 
relationship has been observed in humans, this has been clearly demonstrated in 
experimental tumor models [7, 8, 9]. 
High dose IL-2 therapy is associated with severe systemic toxicity, characterized 
by the malfunction of vital organs [6]. This does prohibit the systemic application of 
doses with optimal antitumor effects [10, 11]. Since hepatic metastases derive 
their blood supply almost totally from the hepatic artery [12, 13], higher local IL-2 
levels can be achieved by intraarterial administration. High local levels of IL-2 
may lead to increased numbers of activated liver associated large granular 
lymphocytes (LGL) and increased numbers of LGL in the liver as has been shown 
in rats by Bouwens and coworkers [14]. Moreover high local IL-2 levels may lead 
to optimal activation of tumor infiltrating lymphocytes (TIL), which are known to be 
abundantly present in colorectal hepatic metastases [15]. The regional advantage 
of achieving high levels of cytokines with minimal systemic toxicity has been 
observed in other regional seUings such as after intracavitary administration [16]. 
Therefore we performed a phase IA-B study in patients with unresectable liver 
metastases of colorectal cancer in order to determine the maximal dose of IL-2 
that can be administered via the hepatic artery for a prolonged period of time. 
64 
Chapter 3 
PATIENTS AND METHODS 
Eligibility criteria 
Patients were required to have histologically confirmed unresectable measurable 
hepatic metastases of colorectal cancer not exceeding 50% of liver volume. 
Patients were required to have no signs of extrahepatic disease on CT scans of 
the brain, thorax and abdomen. Other inclusion criteria were: age < 70 years, no 
prior chemotherapy or radiotherapy during the 4 weeks prior to the administration 
of IL-2, no prior immunotherapy, a Karnofsky performance status:>. 80, no prior 
malignancies or concurrent second primary malignancies, no significant cardio-
vascular, renal, pulmonary or central nervous system disease, no active infections, 
a white blood cell count> 4,000/ml, platelets> 100,000/ml, hematocrit> 30%, 
partial thromboplastin time, prothrombin time, creatinine and bilirubin serum levels 
within the institution's normal range. Patients with a positive test for anti-human 
immune deficiency viral (anti-HIV) antibodies or hepatitis-B-surface antigen 
(HBsAg), and requirements for corticosteroids administration were excluded. 
Informed consent was obtained from all patients prior to study entry. 
Study design 
A preoperative hepatic arteriogram that included celiac and mesenteric angiograp-
hy was done before catheter placement to define the arterial blood supply of the 
liver. Patients were excluded if there was evidence of anomalous hepatic arterial 
anatomy. At laparotomy the catheter was placed into the gastroduodenal artery 
and positioned at the junction with the common hepatic artery. Ligation of the 
distal gastroduodenal artery, right gastric artery, and any other branches supplying 
the stomach and duodenum arising from the common hepatic distal to the 
gastroduodenal take-off was performed. A cholecystectomy was performed. A 
Port-a-Cath® (PAC) was implanted in a subcutaneous pocket overlying the lower 
part of the sternum or the right chest wall. After canulation the patency of the 
catheter was checked. The catheter was flushed twice daily with 5000 IU heparin 
until IL-2 administration. 
The administration of recombinant human IL-2 (Proleukin® Chiron BV, Amsterdam, 
NL) was instituted 2 weeks after the PAC placement. Therapy consisted of the 
continuous hepatic artery infusion (HAl) of IL-2 in 2 cycles of 12 days at 3 week 
intervals according to a dose-escalation scheme. This intrapatient dose escalation 
scheme was chosen since IL-2 has a relative short half life (t 1/2 a = 7 minutes 
and t 1/2 P = 30-60 minutes) so that by the time the second cycle was given most 
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if not all the side effects from the first cycle might have already disappeared. This 
procedure would require fewer patients than a more conventional phase I study 
design. 
Dose escalation scheme and dose adjustment 
According to the intrapatient dose escalation scheme the dose administered during 
the second cycle was twice the dose of the first cycle as is illustrated in Table 1. 
Three eligible patients were to be entered per scheme. In the first cycle, the 
patients received IL-2 for 12 days, followed by a rest period of 3 weeks. If toxicity 
was acceptable in the first cycle and the patients had recovered, he/she was then 
to receive a second cycle, identical to the first but at a higher dose. If no dose 
limiting toxicity occured in 2/3 patients then the next 3 patients were to be entered 
in the next scheme. If 2/3 patients experienced dose limiting toxicity during the first 
cycle of a scheme, the next 3 patients were to be treated with the dosage used in 
the second cycle of the previous scheme. This dose was then to be considered 
the maximal tolerated dose (MTD). If in 2/3 patients unacceptable toxicity occured 
during the second cycle of a scheme, then the next 3 patients were to be treated 
with the dosage used in the first cycle of this scheme, with no dose escalation for 
the second cycle. This dose was then to be considered the MTD. Patients with 
stable disease (SO) or better after 2 cycles should receive 1-2 additional cycles 
after a 4 weeks rest period. The dose of this cycle should be the highest dose 
previously given to the patient, not exceeding the MTD. 
Table 1. Dose escalation scheme 
IL-2 dosage (10' IU/m'/day x 12) 
Scheme I cycle 1 1.5 
cycle 2 3 
Scheme II cycle 1 6 
cycle 2 12 
Scheme III cycle 1 18 
cycle 2 24 
Scheme IV cycle 1 30 
cycle 2 36 
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Follow-up studies and toxicity- and response assessment 
During IL-2 infusions, daily: vital signs, weight (q 12 hrs), hematology (including 
differential and platelets), electrocardiogram (EGG) (if indicated), chest-X-ray (if 
indicated), survey for infection (if indicated), once every two days the following 
parameters were analysed, total serum bilirubin, serum creatinine, LDH, alkaline 
phosphatase, ASAT, ALAT, gamma-GT. 
Weekly during rest periods: weight, hematology (including differential and plate-
lets), total serum bilirubin, serum creatinine, LDH, alkaline phosphatase, ASAT, 
ALAT, gamma-GT, GEA. 
Within 4 weeks after treatment completion: relevant scans for tumor assessment, 
GEA. 
Toxicity was recorded using the WHO grading system [17J. For toxicities not 
included in the WHO guidelines, a grading system was used ranging from mild 
(grade I) to life-threatening (grade IV). Tumor response was classified using 
standard WHO criteria [17J. Duration qf response and survival were calculated 
from the day of treatment initiation. 
RESULTS 
Fourteen patients entered the study, but five had to be excluded after arteriograp-
hy because of an anomalous arterial anatomy. The characteristics of the 9 
remaining eligible patients are shown in table 2. All patients had liver metastases 
in both lobes. No complications occurred in the 2 week period between the PAG 
placement and the start of IL-2 treatment. 
Table 2. Patients' characteristics 
Sex males 6 
females 3 
Age median 51 years 
range 38-64 
Karnofsky median 100 
range 90-100 
Prior therapy surgery all 
systemic therapy l' 
radiotherapy 1 
• 5FU intravenously + FUDR intra-arterially 
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The distribution of patients per dose level and the reasons for treatment disconti-
nuation are shown in table 3. 
Table 3. Patients per dose level and reasons of treatment discontinuation 
IL-2 dose patient treatment discontinuation reasons 
no. duration 
(days) 
1.5 x 10' IU/m'/day x 12 1 6 thrombosis + PAC dislocation 
2 12 
3 12 
4 12 
5 12 
3 x 10' IU/m'/day x 12 2 12 
3 2 thrombosis 
4 12 
5 12 
6 x 10' IU/m'/day x 12 6 12 
7 12 
8 12 
9 7 thrombosis 
12 x 10'IU/m'/dayx 12 6 12 
7 0 thrombosis + dislocation PAC 
8 6 dislocation PAC + upper GI 
bleeding 
Patient no. 1 received 6 days of IL-2 after which a dehiscence of the laparotomy 
wound was noted. An angiogram revealed thrombosis of the hepatic artery and 
dislocation of the catheter tip into the peritoneal cavity. Patient no. 3 received the 
first cycle of IL-2 without any problems. On the third day of the second cycle the 
catheter appeared obstructed and blood could not be withdrawn from the PAC. An 
angiogram revealed thrombosis of the hepatic artery. In an effort to restore the 
patency of the catheter a laparotomy was performed. Due to massive adhesion 
around the hepatic artery no further attempt could be made to isolate the artery. 
Patient no. 6 received 2 cycles without experiencing severe toxicities. However, at 
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the end of the second cycle the PAC appeared occluded due to thrombosis of the 
hepatic artery as seen on angiography. In patient no. 7 thrombosis of the hepatic 
artery and dislocation of the catheter tip was noted on angiogram after the first 
cycle. Patient no. 8 experienced an upper gastro-intestinal (GI)-bleeding during the 
second cycle. At gastroduodenoscopy the source of the bleeding appeared to be 
in the duodenum. Angiography revealed that the catheter tip was dislocated 
outside the gastroduodenal artery, with an aneurysm of the gastroduodenal artery 
adjacent to the duodenal wall, resulting in the upper GI-bleeding. Embolization of 
the hepatic artery was succesfully performed. Patient no. 9 had problems with the 
delivery of IL-2 on the ninth day of the first cycle which was found to be related to 
thrombosis of the hepatic artery, dislocation of the catheter and intimal dissection 
of the gastroduodenal artery, as revealed by angiography. No attempt was made 
to restore the catheter because of coinciding progressive disease (PO). IL-2 
related toxicity is summarized in Table 4. At the dose levels 1.5 and 3.0 X 10' 
IU/day only few and moderate side effects were noted. None of the patients 
developed fever, flu-like symptoms, gastrointestinal symptoms, pulmonary, renal or 
hepatic toxicity. Apart from a mild rise in serum levels of alkaline phosphatase and 
gamma-GT no signs of hepatic toxicity were noted. Hematologic toxicity only 
consisted of a mild leukocytosis and eosinophilia. At the dose levels of 6 x 10' 
IU/day severe but reversible renal and hepatic toxicity was observed. Four patients 
started at this dose level. Two of them (patients no. 7 and 9) developed a 
thrombosis of the hepatic artery during the first cycle. Patient 9 also developed 
grade III hepatic toxicity, another reason to stop the administration. Bilirubin levels 
returned to normal rapidly. Patient no. 7 developed grade III hepatic and renal 
toxicity at the end of the first cycle. During the treatment free period a thrombosis 
of the hepatic artery was noted with dislocation of the PAC. Patient no. 6 also 
received the dose of 12 x 10' IU/day with only moderate side effects. She 
experienced high fevers, fatigue and some mild nausea and vomiting, and at the 
end of the second cycle she developed a thrombosis of the hepatic artery. As 
mentioned previously, patient no. 8 developed an upper GI-bleeding during the 
second cycle. None of the patients developed severe cardiovascular, pulmonary, 
renal, or CNS toxicity. Dose limiting toxicity in 2 patients was hepatic toxicity 
probably related to IL-2 induced cholestasis. Apart from the rise in serum bilirubin 
levels, a 2 to 4 fold increase in alkaline phosphatase, SGOT, SGPT and gamma-
GT levels was noted. One patient had stable disease for a period of 6 months, the 
other 8 patients progressed. 
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Table 4. Toxicity in relation to Dose Level 
IL-2 dose levels/m'lday 
TOXICITY 1.5 x 10' IU 3x 10'IU 6x 10'IU 12x106 1U 
5 pts 4 pts 4 pts 2 pts 
Mild toxicity 
Flu-like symptoms - - 4 1 
Fever> 39'C - - 3 1 
Chills - - 3 1 
Nausea/vomiting - - 3 1 
Moderate toxicity 
Skin rash - - 3 1 
Arthritis/-algia - - 1 -
Fatigue 1 1 2 1 
Leukocytes 
10-15,000/ml 4 3 - -
15-20,000/ml - - 4 1 
Eosinophilia> 10% 2 2 3 1 
Hepatic enzymes ;;,; 50% 2 2 4 1 
Severe Toxicity 
Creatinin > 3.0 mg/dL - - 1 -
Bilirubinemia ;;,; 4 mg/dL - - 2 -
DISCUSSION 
The results of this study indicate that the dose limiling toxicity of prolonged 
administration of IL-2 via the hepatic artery is hepatic toxicity and that relatively 
little systemic toxicity is observed at the maximum tolerated dose (MTD) of 
between 6 and 12 x 106 IU/m2/day. This MTD corresponds with the results 
reported by Mavligit and coworkers [18] using a 5-day continuous infusion of IL-2 
via the hepatic artery (ie. 9 x 10' IU/m'lday) and is about 50% of the MTD obser-
ved with 5-day continuous intravenous infusion of IL-2 [19]. 
The period of 12 days continuous Infusion of IL-2 in our study is however signifi-
cantly longer than the 5-day treatment cycles in the other studies. It may well be 
that this prolonged infusion period was related to the very high rate of thrombotic 
catheter related complications observed in this study. Using an identical surgical 
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technique in a previous chemotherapy hepatic artery infusion protocol also not 
applying routine heparinization during drug infusion, we observed a complication 
rate of less than 7 % as opposed to a 67% thrombosis rate of the hepatic or 
gastroduodenal artery in the present study. 
Interleukin-2 causes substantial endothelial damage in the form of endothelial 
swelling and the appearance of pores between endothelial cells [20J. It also 
activates the coagulation and fibrinolytic systems in vivo, and these changes 
resemble the perturbations observed after tumor necrosis factor-a (TNFa) 
administration [21J. Moreover through the induction of TN Fa and IL-1 focal 
thrombosis may be induced in a Schwartzman type reaction [20, 22, 23J, believed 
to be a possible cause for transient focal neurological deficits that may complicate 
IL-2 therapy [24J. The presence of a corpus alienum in the hepatic artery may 
cause turbulence in the blood stream facilitating the aggregation of blood platelets. 
The addition of heparin during IL-2 administration was avoided since heparin is 
diluted in solvents which caused precipitation of Proleukin®. Moreover, Proleukin® 
should not be mixed with other drugs. Of note, thrombosis of the hepatic artery 
was also described by others during hepatic arterial infusion of floxuridine (FUDR) 
in patients with liver metastases from colorectal cancer [5, 25J. Apparently a small 
caliber artery such as the gastroduodenal artery is not suited for prolonged IL-2 
infusions. Tumor responses were not observed in this study. This disappointing 
result is in accordance with the scarce literature on this approach. Mavligit and 
coworkers reported on 14 patients with 5-day continuous IL-2 infusions via the 
hepatic artery and 14 patients with infusions via the splenic artery. They observed 
one partial remission in each arm of the study [18J. Klasa [26J reported only 2 
minor responses in 20 patients treated by 5-day splenic artery infusions with IL-2. 
Especially in Japan studies have been performed on the locoregional application 
of LAK cells. Okuno and coworkers [27J infused only LAK cells via the hepatic 
artery in a patient with un resectable hepatoma without achieving a CT-
documented response. However the patient had a transient significant decrease in 
alpha-foetoprotein levels and in ascites after therapy. Recently, Matsuhashi et al. 
[28J reported PRs in 2 out of 5 patients with hepatocellular carcinoma, treated by 
both LAK cell and IL-2 infusions via the hepatic artery. No responses were 
observed in ten patients with hepatocellular carcinoma after the injections of LAK 
cells via the hepatic artery in combination with the systemic adminstration of IL-2 
[29J. Direct injections of IL-2 into the tumor in 5 patients with hepatocellular 
carcinoma resulted in partial remissions in 2 patients in one report [30J, but no 
71 
Chapter 3 
responses were observed in another study where both LAK cells and IL-2 were 
injected into the tumors of patients suffering from hepatocellular carcinoma [31]. 
Although these clinical studies demonstrate that incidental antitumor responses 
can be observed after the locoregional administration of IL-2 with or without LAK 
cells the overall results are disappointing. 
With respect to hepatic artery infusion of IL-2 we must also take into account that 
a significant percentage of patients (in our study 5 out of 14) are not suited for 
hepatic artery infusion therapy because of anatomical variations. 
We cannot recommend this approach in treating hepatic metastatic disease. 
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SUMMARY 
Treatment using a combination of 5-Fluorouracil (5-FU), interferon-alpha (IFNa-
2a), and interleukin-2 (IL-2) has been shown to mediate disease regression in 
selected patients with advanced colorectal cancer. This phase II study was 
designed to evaluate the anti-tumour activity and toxicity of the combination of IL-
2, IFNa-2a and 5-FU in patients with advanced colorectal cancer. Forty-four 
patients with metastatic colorectal cancer were treated, predominantly at an 
outpatient basis, with subcutaneous IFNa-2a and IL-2 three times per week 
followed by once a week bolus intravenous 5-FU injections. There were 6 (14%) 
partial responses among the 43 evaluable patients (95% confidence interval [GI] = 
5%-28%). Twenty-four patients had stable disease (56%) and 13 patients (30%) 
showed progressive disease. The median time to progressive disease in 43 
patients was 19 weeks (range 2-72 weeks), and in responders 34 weeks (range 
24-30 weeks). The median overall survival was 47 weeks (range 2-85 weeks) and 
in responders 60 weeks (range 35-71 weeks). Treatment related toxic effects 
included fatigue, nausea and vomiting. Granulocytopenia was the main reason for 
the dose reductions or treatment interruptions in 32 out of 44 patients. One patient 
died of toxiCity due to renal failure. Serial assessments of immunophenotyping and 
cytolytic activities of peripheral blood lymphocytes did not show changes in the 
numbers of circulating natural killer (NK) cells or in the levels of NK and 
Iymphokine-activated killer (LAK) cytolytic activities. This regimen of IL-2 and 
IFNa-2a with 5-FU has only modest antitumour activity in advanced colorectal 
cancer. 
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INTRODUCTION 
The Irealment of advanced and metastatic colorectal cancer remains unsatisfac-
tory despite the availability of many cytotoxic agents. Since 1957 5-fluorouracil (5-
FU) has been the mainstay of therapy for disseminated colorectal cancer 
(Heidelberg, 1957). 
Biochemical modulation of the effect of 5-FU with methotrexate or with leucovorin 
has marginally improved survival (Moertel, 1994). Another approach appeared to 
be the combination of 5-FU with interferon-alpha (IFNa-2a), (Wadler et a/., 1989; 
Pazdur et a/., 1990; Kemeny et a/., 1990). A potential way to further improve the 
reported results was suggested by Onodera et al. (Onodera et a/., 1990). They 
studied the effects of 5-FU + leucovorin on the interleukin-2 (IL-2) related 
lymphocyte immune response. Rather than being immunosuppressive, the use of 
5-FU + leucovorin appeared to augment natural killer (NK)- and Iymphokine 
activated killer (LAK) activity. Promising clinical results were recently reported by 
Yang et al. (Yang et a/., 1993) applying a combination of 5-FU, leucovorin and IL-
2, and by Atzpodien et al. (Atzpodien et a/., 1994) using a combination of 5-FU, 
IL-2 and IFNa-2a in metastatic colorectal cancer. These studies provided the basis 
for the design of the here reported study with a schedule of IL-2, IFNa-2a and 5-
FU in patients with advanced colorectal cancer. We used the combination of IFNa-
2a and IL-2 upfront based on preclinical and clinical data suggesting synergistic 
antitumour activity of this schedule (Cameron et a/., 1988; Rosenberg et a/., 1989). 
IFNa can upregulate major histocompatibility antigens class I (MHC-I) expression 
on tumour cells (Weber and Rosenberg, 1988) which are usually downregulated 
when the tumour becomes more invasive (Feldman and Eisenbach, 1991; Smith et 
a/., 1988). It augments LAK-activity (Chikhala et a/., 1990), and it has direct 
antiproliferative and cytotoxic properties against tumour cells (Gresser, 1989). 
These properties may alter the malignant phenotype of tumour cells so that they 
become more susceptible to the cytolytic activity of immune cells. 
MATERIALS AND METHODS 
Patient eligibility 
Patients were required to have histologically confirmed metastatic or locally 
advanced measurable adenocarcinoma of the colon or rectum, not previously 
treated with systemic therapy. Patients were required to be ,;; 75 years of age, to 
have a neutrophil count of ;" 1.5 x 10'/1 and a platelet count of ;" 100 x 10'/1, 
serum bilirubin ,;; 1.25 x upper limit of normal unless due to metastatic liver 
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disease, serum creatinine s 1.25 x upper limit of normal, life expectancy :?: 3 
months, normal cardiopulmonary function as assessed by non-invasive clinical 
examination and a Karnofsky score :?: 70. Patients with evidence of symptomatic 
CNS metastases, positive for anti-HIV antibodies or HBsAg, or requiring 
glucocorticoid administration were excluded. Written informed consent was 
obtained from all patients prior to entry into this study. 
Pretreatment evaluation 
Pre-study screening included clinical assessment, haematology tests including 
white blood cell count and differential, platelet count and haemoglobin, 
biochemistry including bilirubin, alkaline phosphatase, ALAT, ASAT, electrolytes, 
creatinine, special laboratory tests including prothrombin, partial thromboplastin 
time, thyroxine, thyrotropin, thyroglobulin, anti-thyroid microsomal antibodies, HIV-
antibody and HBs-antigens, chest X-ray, ECG and computer tomography (CT) of 
the chest and abdomen. Serum samples of anti-IL-2 and anti-IFNa-2a antibodies 
were taken before treatment and were repeated before each cycle. Antibody 
analysis was performed by enzyme immunoassay (EIA) in screening for binding 
antibodies and by a biological assay for the detection of neutralizing antibodies. 
Treatment 
The treatment regimen is shown in Table 1. The first 6-weeks cycle consisted of 
IFNa-2a (Roferon®-A, Hoffmann La Roche Ltd., Basel, CH) 9 MIU subcutaneously 
(sc) 3 times a week (tiw) for 6 weeks except for day 1 in week 2; IL-2 (Proleukin®, 
Chiron BV, Amsterdam, NL) 9 MIU sc tiw, weeks 2 to 5, preceded by loading 
doses of 9 MIU sc 3 times a day on days 1 and 2 in week 2; and 5-FU at a dose 
of 750 mg/m2/day as a continuous intravenous (iv) infusion on days 15 to 20 
followed by iv bolus injections of 750 mg/m2 on day 29 and 36. Thereafter, a 
maximum of five 4-weekly cycles were administered, consisting of IFNa-2a 9 MIU 
sc tiw for 4 weeks; IL-2 9 MIU sc tiw for 3 weeks; and 5-FU 750 mg/m2 iv bolus 
weekly for 4 weeks. 
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Table 1 Immunotherapy in advanced colorectal cancer: Treatment scheme 
Drug Dose Schedule 
IFNa- 9 million U sc Cycle 1: 3 times per wk, wk 1 and 3 through 6 
2b 2 times per wk, wk 2 
Cycles 2-6: 
3 times per wk, wk 1 through 4 
IL2 9 million IU sc Cycle 1: thrice daily, d 1 +2 and once daily, 
d 3 in wk 2; 
3 times per wk, wk 3 through 5 
Cycles 2-6: 
3 times per wk, wk 1 through 3 
5-FU 750 mg/m2/day Cycle 1: CIV d 1-5, wk 3 
IV bolus once weekly, wk 5+6 
Cycles 2-6: 
IV bolus once weekly, wk 1 through 4 
Eva/uation of toxicity, dose modifications and concomitant medication 
Toxicity was graded according to the WHO criteria (WHO Handbook, 1979) and 
assessed weekly. 
No dose modifications were required in case of grade I toxicity. In case of grade II 
toxicity, the dose of 5-FU had to be reduced to 500 mg/m2; IFNa-2a to 4.5 MIU 
and IL-2 to 4.5 MIU. If recovery occurred within 1 week, the 3 drugs were given at 
full dose. If the toxicity recurred, the decreased dose was re-introduced. In case of 
grade III toxicity, all 3 drugs were discontinued. If recovery to grade 0 occurred 
within 28 days of treatment discontinuation, 5-FU was resumed at 500 mg/m2, 
IFNa-2a at 4.5 MIU and IL-2 at 4.5 MIU. In case no full recovery occurred within 
28 days or the occurrence of any grade IV toxicity, the patient went off study. 
Patients could be given paracetamol 500 mg 6 times daily to reduce flu-like symp-
toms; codeine phosphate 30-60 mg 4 times daily for diarrhoea; sucralfate mouth-
wash for stomatitis and metoclopramide or a 5HT3 antagonist for nausea and/or 
vomiting. Patients were substituted with levothyroxine in case of hypothyroidism. 
Other concomitant antitumour therapies or systemic steroids were not allowed. 
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Definition of response and statistical analysis 
Tumour assessment was performed according to WHO criteria (WHO Handbook, 
1979). Evaluation of response was performed after the 2nd, 4th and 6th cycle. 
Further therapy was withheld in case of progressive disease (PD) at any time. In 
case of no response in the first 10 patients treated for at least 10 weeks, the trial 
was to be terminated. Otherwise the sample size was to be large enough to 
confirm or exclude a 40% response rate by 95% confidence intervals using 
Pearson-Clopper range limits. 
Overall survival and time to disease progression were calculated from the start of 
treatment until the date of death or progression. The Kaplan-Meier method was 
used to calculate the probability of survival or time to progression. 
Immunological monitoring 
Absolute numbers of lymphocyte subsets and cytolytic activities of peripheral 
blood mononuclear cells (PBMC) were assessed immediately prior to and at the 
end of the 1", 20d and 3,d week of the first cycle, immediately prior to the 20d, 3,d 
and 4fu cycle (i.e., weeks 6, 10 and 14) and at the end of the 4fu cycle (i.e., week 
18). The PBMC were isolated by Ficoll-Isopaque density centrifugation of 30 ml 
heparinized venous blood samples. An aliquot was processed immediately for 
immunophenotyping and the remainder was cryopreserved in liquid N, to allow the 
cytotoxicity assays on all samples from a single patient to be tested on the same 
occasion to exclude the effects of interassay variability. The lymphocyte subsets 
defined by CD3 and CD56, CD4 and CD8, CD16 and CD19 monoclonal antibodies 
were assessed by multicolor immuno-fluorescence and flow cytometry as 
described elsewhere (Gratama et al., 1996). Cytolytic activities were determined 
by a standard 3-hour 5'Cr-release assay as described previously (Gratama et al., 
1993). The K562 erythromyeloid leukemia cell line and the Daudi Burkitt's lympho-
ma cell line were used as sources of target cells for the assessment of NK and 
LAK activities, respectively. 
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RESULTS 
Patients 
Fifty-one patients were entered in this study between January 1991 and 
September 1992. Six patients were considered ineligible because they did not fulfil 
the inclusion criteria. One patient withdrew consent, and another patient was not 
evaluable for response because no post-treatment tumour assessment was 
available. Thus, 43 patients were evaluable for response and 44 for toxicity. 
The patient characteristics are shown in Table 2. 
Table 2 Patients' characteristics 
Sex males 25 
females 19 
Age median 59 
range 31-71 
Karnofsky 28 
90-100 12 
80 4 
70 
Sites of disease 35 
liver 11 
lung + pleura 6 
Iymphnodes 4 
peritoneum 4 
skin 13 
other 
Evaluation of toxicity 
A total of 159 treatment cycles were given with a median of 4 per patient. One 
patient died due to treatment related renal failure. There were no other cases of 
drug-related renal toxicity neither were there other grade IV toxicities. Table 3 
summarizes the percentage of patients experiencing WHO grade II-IV toxicities. 
The most frequently occurring grade III adverse events were fatigue, nausea and 
82 
Chapter 4 
vomiting. Thirty-two patients required one or more temporary dose reductions or 
treatment interruptions, which was mostly due to granulocytopenia. 
The mean total dose per cycle of the trial medication in relation to the planned 
dose is shown on Table 4. It appears that the percent dosage actually given 
decreases with the number of cycles. 
Table 3 Side effects observed in 44 patients (159 courses, analyzed according to 
the highest toxicity-grade per patient) 
Adverse events' No. of WHO Grade (%) 
patients II III IV 
Fever 34 63 7 -
Fatigue 34 46 12 -
Nausea-vomiting 32 49 23 -
Stomatitis 19 28 7 -
Diarrhoea 24 28 2 -
Cutaneous 14 14 - -
Local inflammation at injection site 10 21 - -
Hypotension 9 9 - -
Granulopenia 16 23 10 -
Renal 1 - - 2 
Table 4 Mean total dose per cycle 
Cycle IL2 (MIU) IFNa (MIU) 5-FU (mg) 
received (%planned) received (%planned) received (%planned) 
1 134 (93%) 128 (84%) 9151 (96%) 
2-6 55 (68%) 73 (68%) 4002 (73%) 
Immunological monitoring 
Lymphocyte subset enumerations and assays of cytolytic functions were 
performed in 24 of the 43 evaluable patients (Figure 1). Prior to therapy, the 
median values of the absolute numbers of NK lymphocytes (CD56+,3-; panel A) 
and cytotoxic/suppressor T lymphocytes (CD8+; panel D) were at the upper limit of 
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the normal range and the absolute number of lymphocytes (CD3+; panel B) were 
within the normal range, whilst that of the helper/inducer T lymphocytes (CD4+; 
panel C) was slightly below the normal range. These lymphocyte subset counts 
remained essentially unchanged throughout the period of treatment and shortly 
thereafter. Prior to therapy, the median NK activity of peripheral blood lymphocytes 
was increased (panel E), whilst LAK activity was absent in most donors (panel F). 
The median values of both activities increased slightly during the first therapeutic 
cycle to persist at those levels thereafter, i.e., increased relative to the normal 
range for NK activity and within the normal range for LAK activity. 
Antibody formation against IL-2 and IFNa-2a 
Serial serum samples of 29 patients were available. Thirteen (45%) developed 
antibodies against IFNa-2a, 6 (21%) against IL2. Three (10%) had antibodies 
against both IL2 and IFNa. Two of these 3 patients achieved a PR despite the 
presence of neutralizing antibodies. Two patients (7%) had anti-IFNa-2a antibodies 
at baseline; none had anti-IL-2 antibodies at baseline. The development of 
antibodies did not appear to be related to specific side effects or severity of side 
effects. 
Response to treatment 
Six of the 43 patients evaluable for response achieved a partial response. Thus, 
the overall response rate was 14% (95% confidence interval 5-28%). Twenty-four 
patients (56%) had stable disease and 13 (30%) showed progressive disease. The 
median time to progressive disease in 43 patients was 19 weeks (range 2-72), and 
in responding patients 34 weeks (range 24-36). The median overall survival was 
47 weeks (range 2-85), and in responding patients 60 weeks (range 35-71). 
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Figure 1 Median absolute numbers and ranges of CD3-,56' NK lymphocytes (panel A), 
CD3' T lymphocytes (panel B), CD4' helper/inducer lymphocytes (panel C) and CDS' sup-
pressorlinducer lymphocytes (panel D), and NK (panel E) and LAK (panel F) cytolytic 
activities of peripheral blood mononuclear cells in 24 patients, Logarithmic scales have 
been used for the vertical axes in order to compress the figure, Closed circles and vertical 
bars represent median values and confidence limits as defined by the 5th and 95th 
percentiles, respectively, The shaded areas represent the normal range as defined by the 
5th and 95th percentiles of 72 (panels A to D) and 29 (panels E and F) apparently healthy 
control persons, Cytolytic activities were expressed as the weighed mean of specific lysis 
of 4 effector to target (E:T) ratios (i,e" ranging between 50 and 6,3), calculated for E:T 
ratio = 17,7 (Gratama et al_, 1993)_ 
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DISCUSSION 
Preclinical studies have previously shown a synergistic interaction between 5-FU 
and IFNa (Miyoshi et al., 1983; Elias and Crisman, 1988), which formed the basis 
to investigate this combination in patients with advanced cancer. Initial clinical 
studies (Wadler et al., 1989; Pazdur et a/., 1990; Kemeny et a/., 1990; William et 
a/., 1993) had suggested higher response rates than usually achieved with 5-FU 
alone. 
Other preclinical data suggested synergy between IL-2 and IFNa (Cameron et al., 
1988), which appeared to be confirmed in clinical studies in melanoma and renal 
cancer (Rosenberg et al., 1989; Marincola et al., 1995). The logical next step was 
to study the combination of the 3 drugs. However, we observed a meager 14% 
partial response rate with a median response duration of 34 weeks. Although 78% 
of the patients completed at least 2 full courses, 32 of them (63%) required 
treatment interruptions or dose reductions. The most common reason for this was 
granulocytopenia. The majority of these dose modifications occurred during the 
first 2 courses. So, one could argue that the low response rate might be 
attributable to the moderate dose intensity achieved. Another possible reason 
could be the fact that 5-FU in this study was administered after IL-2 and IFNa-2a, 
thereby not taking full advantage of the possible eradication of T-suppressor cells 
with chemotherapy before immunotherapy (Berendt and North, 1980). It was also 
found that 5-FU cy1otoxicity was enhanced by concomitant or subsequent 
exposition to IFNa, while the reverse sequence, IFNa followed by 5-FU, abrogated 
the cy1otoxic effect of 5-FU suggesting that pretreatment with IFNa could protect 
tumour cells (Wadler et al., 1988). Prolonged administration of IFNa (I.e., three 
times a week) can induce a persistent block of tumour cells in Go-G" thus 
reducing the S-phase fraction and therefore diminish the anticancer activity of 5-
FU (Cascinu et al., 1993). To date, we have deliberately chosen a regimen using a 
loading dose of IL-2 and IFNa-2a preceding 5-FU, in order to enable upregulation 
of MHC-I molecules on tumour cells (Weber and Rosenberg, 1988), to augment 
LAK-activity (Chikhala et al., 1990), and to exploit the antiproliferative and 
cy1otoxic properties of IFNa (Gresser, 1989). However, we did not observe any 
changes in the tested immune parameters throughout the study. Occasionally, the 
lack of anti-tumour response has been associated with the development of 
neutralizing antibodies to IL-2 and IFNa used. However, in this study 2 of the 3 
patients who developed neutralizing antibodies against IL-2 and IFNa-2a, 
nevertheless achieved a partial response. 
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As previously stated, at the time this study was designed, interferon-alpha seemed 
to be an effective biomodulating agent for increasing 5-FU activity in the treatment 
of advanced colorectal cancer. However, recently published randomized studies 
were not able to confirm this. 
Hill et al. (Hill et al., 1995a) randomized 155 patients to receive either protracted 
continuous intravenous infusions (civ) of 5-FU at a dose of 300 mg/m'/day for 10 
weeks in combination with IFNa-2b 5 MIU sc tiw, or the civ 5-FU only. In the 5-
FU/IFNa-2b-group there were significantly more episodes of mucositis (p=0.008), 
leucocytopenia (p=O.001), granulocytopenia (p=0.004), and alopecia (p=0.0002). 
The overall response rate in the 5-FU/IFNa-2b-group was 22% and in the 5-FU-
group it was 33% (p=0.12). With a follow-up time of 861 days, the median survival 
in the 5-FU/IFNa-2b-group was 161 days, and in the 5-FU-group it was 193 days. 
The differences did not reach statistical significance. Premature withdrawals due to 
toxicity in both groups of patients were equal and cannot explain the lack of IFNa-
2b benefit. 
The same group (Hill et al., 1995b) performed another randomized controlled 
phase III study in advanced colorectal cancer patients using a different dose and 
scheduling of 5-FU and IFNa-2b. At the start of treatment, 106 patients received a 
contiuous infusion of 5-FU at a dose of 750 mg/m'/d for 5 consecutive days. Fifty-
two patients were randomized to receive IFNa-2b at a dose of 10 MU sc tiw 2 to 4 
hours after initiating 5-FU. During the second week, these patients continued on 
IFN-a-2b and had the first dose of bolus IV 5-FU 750 mg/m'/d at the beginning of 
week 2. Fifty-four patients were randomized to receive 5-FU alone, and this was 
given at the beginning of week 2. Treatment was continued until progression of 
disease or unacceptable toxicity for up to 12 months. In the 5-FUIIFNa-2b-group 
there was significantly more leucopenia (p = 0.013), lymphopenia (p = 0.01), 
depression (p = 0.014), and withdrawal due to adverse events (p = 0.003). There 
were 4 toxic deaths, all of which occurred in patients who received IFNa-2b. The 
overall response rate was 19% (all PRs) in the group that received 5-FU + IFNa-
2b, and 30% in the 5-FU-alone group (3 CRs and 13 PRs) (p = 0.21). Neither 
progression-free survival nor overall median survival showed any significant 
differences in the two groups. 
Likewise, in a randomized phase III study performed by the Corfu-A Study Group 
(Corfu-A-Study Group, 1995), the biochemical modulation of 5-FU by either IFNa-
2a or leucovorin was studied. In 247 patients 5-FU was given at a dose of 370 
mg/m'/day Lv. bolus for 5 days in combination with leucovorin (LV) 200 mg/m'/day 
Lv. for 5 days, repeated every 4 weeks. The other group consisted of 245 patients, 
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who received 5-FU 750 mg/m'/day civ for 5 days, followed after a 9-day interval by 
a weekly bolus Lv. injection at the same dose in combination with IFNa-2a 9 MIU 
s.c. tiw throughout the treatment period. In the 5-FU/LV-group there were more 
gastrointestinal toxicities while the 5-FU/IFNa-2a-group the regimen was more 
myelosuppressive (p=O.0001). The overall response rate in the 5-FU/LV-group was 
18% and in the 5-FU/IFNa-2a-group it was 21% (p=0.57). After a follow period of 
20 months, the median survival time for the 5-FU/LV-group was 11.3 months 
versus 11 months for the 5-FU-IFNa-2a-group (p=0.98). These results suggested 
that biochemical modulation of 5-FU by either leucovorin or IFNa-2a yield 
comparable response and survival data. The addition of IFNa-2a to high dose 5-
FU plus leucovorin was studied by Kohne et al (Kohne et a/., 1995) in a 3-arm 
randomized study. Chemotherapy-naive patients were randomized to receive 5-FU 
2600 mg/m' Lv. as a 24-hour infusion, combined with either leucovorin 500 mg/m' 
as a 2-hour infusion (arm A), or IFNa-2b 3 MIU sc tiw (arm B), or the combination 
of leucovorin plus IFNa-2b as in arms A and B (arm C). Treatment was repeated 
weekly for 6 weeks followed by a 2-week rest period until tumour progression. 
Because of the occurrence of 2 toxic deaths (septicaemia due to mucositis and 
diarrhoea) among the first 17 patients treated in arm C, the 5-FU dose was 
reduced to 2000 mg/m' for all patients in arm C. Despite this dose· reduction 
another patient died of severe diarrhoea. An interim analysis was then performed 
after the first 93 of 149 randomized patients. Among patients treated in arm A, and 
in arm C, objective tumour responses occurred in 39% (95% confidence interval; 
21-56%) and in 38% (95% confidence interval; 20-56%, respectively). This interim 
analysis showed that the rates of objective responses observed in treatment arm A 
and C were equivalent. Due to the increased toxicity observed in arm C this treat-
ment arm was closed. No report on the response rate in treatment arm B was 
given because randomization between arm A and arm B was continuing. The 
authors concluded that the addition of IFNa-2b to 5-FU plus leucovorin did not 
increase efficacy and was associated with life threatening toxicity. 
Heys et al (Heys et al., 1995) performed a randomized controlled phase III study 
comparing the efficacy of 5-FU plus leucovorin (5-FU/LV) with 5-FU plus 
leucovorin plus IL-2 (5-FU/L VlIL2) in patients with unresectable or metastatic 
colorectal cancer. In the 5-FU/LV group, 68 patients received 5-FU 600 mg/m' day 
bolus Lv. once a week for 6 weeks in combination with leucovorin 25 mg/m'/day 
bolus Lv. to be repeated after 2 weeks rest. In the 5-FU/LV/IL2 group, 65 patients 
received IL-2 18 MIU/m'/day civ from day 1-5, followed by 5-FU 600 mg/m'/day 
bolus Lv. in combination with leucovorin 25 mg/m'/day bolus Lv. on days 7, 14 and 
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21. This treatment regimen was repeated on day 28. The objective response rates 
were not significantly different in both arms, 16% for 5-FU/LV and 17% for 5-
FU/LVIIL2. With a follow-up duration of 30 months, there was no difference in the 
median survival, being 11.7 months and 11.4 months (p=O.II), respectively. 
Finally, in a small phase II study in 18 patients Ridolfi et al. (Ridolfi et al., 1994) 
only achieved a 5% response rate using 5-FU, leucovorin, IL-2 and interferon-a, in 
advanced, pretreated colorectal cancer. 
Despite different scheduling of IFNa and IL-2 in combination with different doses 
of 5-FU +/- leucovorin, all of these studies show that the addition of IFNa and IL-2 
failed to improve clinical benefit over 5-FU alone. Apparently observations from 
laboratory studies cannot be translated clinically. 
We conclude that our schedule of IL-2 and IFNa-2a combined with 5-FU has only 
modest antitumour activity, which does not appear to be better than what can be 
expected of 5-FU alone. This is confirmed by randomized studies which failed to 
confirm the ability of IFNa andlor IL-2 to augment the efficacy of 5-FU. In our 
opinion, further clinical investigation of IFNa and IL-2 in combination with 5-FU in 
advanced colorectal cancer is not justified. 
REFERENCES 
ATZPODIEN J, KIRCHNER H, HiiNNINEN EL, MENZEL T, DECKERT M, FRANZKE A, 
SCHOMBURG A AND POLIWODA H. (1994). Treatment of metastatic colorectal 
cancer patients with 5-fluorouracil in combination with recombinant subcutaneous 
human interleukin-2 and alpha-interferon. Oncology, 51, 273-275. 
BERENDT MJ AND NORTH RJ. (1980). T-cell-mediated suppression of anti-tumour 
, immunity: An explanation for progressive growth of an immunogenic tumour. J. Exp. 
Med., 151, 69-81. 
CAMERON RB, MCINTOSH JK AND ROSENBERG SA. (1988). Synergistic antitumour 
effects on combination immunotherapy with recombinant interleukin-2 and a 
recombinant hybrid alpha-interferon in the treatment of established murine hepatic 
metastases. Cancer Res., 48, 5810-5817. 
CASCINU S, DEL FERRO E, FEDELI A, GRIANTI C, FOGLIETII G, OLIVIERI Q. 
(1993). Cytokinetic effects of interferon in colorectal cancer tumors: Implications in 
the design of the interferon/5-Fluorouracil combinations. Cancer Res., 53, 5429-
5432. 
CHIKHALA NF, LEWIS I, ULCHAKER J, STANLEY J, TUBBS R AND FINKE JH. (1990). 
Interactive effects of a-interferon NO and interleukin-2 on murine Iymphokine-
activated killer activity: analysis at the effector and precursor level. Cancer Res., 501 
1178-1182. 
CORFU-A STUDY GROUP. (1995). Phase III randomized study of two Fluorouracil 
combinations with either interferon alfa-2a or leucovorin for advanced colorectal 
cancer. J. Clin. Oncol., 13, 921-928. 
ELIAS L AND CRISMAN HA. (1988). Interferon effects upon the adenocarcinoma 38 
and HL-60 cell lines; antiproliferative responses and synergistic interactions with 
halogenated pyrimidine anti metabolites. Cancer Res., 48, 4868-4873. 
89 
Chapter 4 
FELDMAN M AND EISENBACH L. (1991). MHC class-I genes controlling the metastatic 
phenotype of tumour cells. Semin. Cancer Bioi., 2,337-346. 
GRATAMA JW, BRUIN RJ, LAMERS CHJ, OOSTEROM R, BRAAKMAN E, STOTER G 
AND BOLHUIS RLH. (1993). Activation of the immune system of cancer patients by 
continuous Lv. recombinant interleukin-2 (rIL-2) therapy is dependent of dose and 
schedule of rIL-2. CUn. Exp. Immunol., 92,185-193. 
GRATAMA JW, SCHMITZ PIM, GOEY SH, LAMERS CHJ, STOTER G AND BOLHUIS 
RLH. (1996). Modulation of immune parameters in patients with metastatic renal cell 
cancer receiving combination immunotherapy (IL-2, IFN-a and autologous IL-2-
activated lymphocytes). In/. J. Cancer, 65, 152-160. 
GRESSER I. (1989). Antitumour effects of interferon. Acta Oncologica, 28, 347-353. 
HEIDELBERG C. (1957). Fluorinated pyrimidines, a new class of tumour inhibitory 
compound. Nature, 179, 663. 
HEYS SD, ERANIN 0, RUGGERI EM, PEIN F, RAINER H, OSKAM R. (1995). A 
phase III study of recombinant interleukin-2, 5-Fluorouracil and leucovorin versus 5-
Fluorouracil and leucovorin in patients with unresectable or metastatic colorectal 
carcinoma. Eur. J. Cancer, 31A, 19-25. 
HILL M, NORMAN A, CUNNINGHAM D, FINDLAY M, WATSON M, NICOLSON V, WEBB 
A, MIDDLETON G, AHMED F, HICKISH T, NICOLSON M, O'BRIEN M, IVESON T, 
IVESON A AND EVANS C. (1995a). Impact of protracted venous infusion 
fluorouracil with or without Interferon Alfa-2b on tumour response, survival, and 
quality of life in advanced colorectal cancer. J. CUn. Oncol., 13,2317-2323. 
HILL M, NORMAN A, CUNNINGHAM D, FINDLAY M, NICOLSON V, HILL A, IVESON A, 
EVANS C, JOFFE J, NICOLSON M AND HICKISH T. (1995b). Royal Marsden 
phase III trial of Fluorouracil with or without Interferon Alpha-2b in advanced 
colorectal cancer. J. CUn. Oncol., 13, 1297-1302. 
KEMENY N, YOUNES A, SEITER R, KELSEN D, SAMMARCO P, ADAMS L, DERBY S, 
MURRAY P AND HOUSTON C. (1990). Interferon alpha-2a and 5-fluorouracil for 
advanced colorectal carcinoma. Cancer, 66, 2470-2475. 
KOHNE CH, WILKE H, HECKER H, SCHOFFSKI P, KAUFER C, RAUSCHECKER H. 
(1995). Interferon-alpha does not improve the antineoplastic efficacy of high-dose 
infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann. Oncol., 
6, 461-466. 
MARINCOLA FM, WHITE DE, WISE AP AND ROSENBERG SA (1995). Combination 
therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic 
cancer. J. CUn. Oncol., 13, 1110-1122. 
MIYOSHI T, OGAWA S, KANAMORI T, NOBUHARA M AND NAMBA M. (1983). 
Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of estab-
lished human cell lines originating from neoplastic tissues. Cancer Lett., 17, 239-
247. 
MOERTEL CG. (1994). Chemotherapy for colorectal cancer. New. Eng. J. Med., 330, 
1136-1142. 
ONODERA H, SOMERS SS AND GUILLOU PJ. (1990). Paradoxical effects of 
5-FU/folinic acid on Iymphokine-activated killer (LAK) cell induction in patients with 
coloreclal cancer. Br. J. Cancer, 62, 1042-1046. 
PAZDUR R, AJANI JA, PATT YZ, WINN R, JACKSON D, SHEPARD B, DUBROW R, 
CAMPOS L, QUARAISHI M, FAINTUCH J, ABBRUZZESE JL, GUTTERMAN J AND 
LEVEN B. (1990). Phase II study of fluorouracil and recombinant interferon alpha-2a 
in previously untreated advanced colorectal carcinoma. J. CUn. Oncol., 8, 2027-
2031. 
RIDOLFI R, MAL TONI R, RICCOBON A, FLAMINI E, FEDRIGA R, MILANDRI C, PEZZI L, 
VELOTTI F, SANTONI A AND AMADORI D. (1994). A phase II study of advanced 
90 
Chapter 4 
colorectal cancer patients treated with combination 5-Fluorouracil plus Leucovorin 
and subcutaneous Interleukin-2 plus Alpha-Interferon. J. Chemofher., 6, 265-271. 
ROSENBERG SA, LOTZE MT, YANG JC, LINEHAN WM, SEIPP C, CALABRO S, KARP 
SE, SHERRY RM, STEINBERG S AND WHITE DE. (1989). Combination therapy 
with interleukin-2 and alpha-interferon for the treatment of patients with advanced 
cancer. J. Clin. Oncol., 7, 1863-1874. 
SMITH MEF, BODMER WF AND BODMER JB. (1988). Selective loss of HLA-A, B, C 
locus products in colorectal adenocarcinoma. Lancet, 1, 823-824. 
WADLER S, SCHWARTZ EL AND GOLDMAN M. (1988). Preclinical and clinical studies 
of 5 fluorouracil (FURA) and recombinant «-2a interferon (IFN) against 
gastrointestinal (GI) malignancies. Clin. Res., 36, 803A. 
WADLER S, SCHWARTZ EL, GOLDMAN M, L YVER A, RADER M, ZIMMERMAN M, ITRI 
L, WEINBERG V AND WIERNIK PH. (1989). Fluorouracil and recombinant alfa-2a-
interferon: An active regimen against advanced calarectal carcinoma. J. GUn. Oneol., 
7, 1769-1775. 
WEBER JS AND ROSENBERG SA. (1988). Modulation of murine tumour major 
histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res., 48, 5818-
5824. 
WHO Handbook for reporting results of cancer treatment, WHO offset publication no. 
48, WHO Geneva, 1979. 
YANG JC, SHLASKO E, RITCHEY JL, LANDRY JG, WHITE DE AND ROSENBERG SA. 
(1993). Combination chemoimmunotherapy for metastatic colorectal cancer using 5-
fluorouracil, leucovorin and interleukin-2. Eur. J. Cancer, 29A, 355-359. 
91 

Chapter 5 
FINAL REPORT OF A PHASE II STUDY 
OF INTERLEUKIN·2 AND INTERFERON·u IN PATIENTS WITH 
METASTATIC MELANOMA 
W.H.J.Kruit'. S.H.Goey', F.Calabresi', A. Lindemann3, R.A.Stahel', 
H.Poliwoda', B.Osterwalder6 and G.Stoter'. 
'Department of Medical Oncology, 
Rotterdam Cancer Institute, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands; 
'Department of Medical Oncology, 
National Cancer Institute Regina Elena, Viale Regina Elena 291,00161 Rome, 
Italy; 
3Department of Hematology and Oncology, 
University Hospital, Hugstetter Str. 55, 0·79106 Freiburg, Germany; 
'Division of Oncology, Department of Medicine, 
University Hospital, CH·8091 ZOrich, Switzerland; 
'Department of Hematology and Oncology, 
University Medical Center, 0·3000 Hannover 61, Germany; 
61nternational Clinical Research Oncology, 
F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4002 Basel, Switzerland 
(British Journal of Cancer, 71: 1319-1321, 1995) 

Chapter 5 
SUMMARY 
Fifty-seven patients with metastatic melanoma were treated with interleukin-2 
(IL2) 7.8 MIU/m'/d as a continuous infusion for 4 days combined with interferon-a 
(IFNa) 6 MIU/m'/d, subcutaneously day 1 +4. The cycle was repeated every 2 
weeks for a maximum number of 13 cycles. Of the 51 evaluable patients one (2%) 
achieved a complete and 7 (14%) a partial response, total response rate 16% (el 
7-29%). Median time to progression and median survival were 2.5 and 11.3 
months, respectively. This regimen of IL2 and IFNa appeared to be only 
moderately active. 
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INTRODUCTION 
Immunotherapy with recombinant interleukin-2 (IL2) has been reported to 
yield a 5-27% response rate in metastatic melanoma (Rosenberg et aI., 1989a; 
Parkinson et aI., 1990; Whitehead et aI., 1991; Rosenberg et aI., 1993; Sparano et 
aI., 1993). Interferon-alpha (IFNa) alone in this group of patients has shown 
response rates of 12-22% (Robinson et aI., 1986; Kirkwood, 1991). 
Based on the synergistic activity of IL2 and IFNa in preclinical experiments 
(Brunda et aI., 1987; Cameron et aI., 1988; ligo et aI., 1988) and on the encoura-
ging results of early clinical trials with this combination (Budd et aI., 1989; Lee et 
aI., 1989; Rosenberg et aI., 1989b), we decided to perform a phase II study. Here, 
we report the final analysis after a median follow-up period of 10.5 months (range 
1.1-47+ months). 
MATERIAL AND METHODS 
Patients 
Fifty-seven patients with metastatic melanoma were entered in the study. 
Eligibility criteria included: age 18-70 years, Kamofsky performance status 60-100, 
no metastases in the central nervous system, no significant cardiovascular history, 
normal pulmonary function, serum bilirubin and creatinine within normal range, 
normal bone marrow function (HCT > 30%, WBC > 4000/ml, platelets > 
100,OOO/ml), normal coagulation parameters, normal serum calcium and negative 
tests for HIV antibody and hepatitis-B antigen. 
Previous treatment with IL2 or IFNa was not allowed. Prior radiotherapy or 
chemotherapy had to be completed at least 4 weeks before entry into the study. 
Corticosteroids were prohibited. 
The protocol was reviewed and approved by the institutional review board 
and the ethical committee of each participating centre. 
Six patients were ineligible; 3 had unmeasurable disease, 2 had brain 
metastases, 1 was pretreated with interferon-2p. Fifty-one patients were evaluable 
for response and toxicity. The patient characteristics are shown in Table I. The 
median time from initial diagnosis to immunotherapy was 24 months (range 1 to 
142 months). 
Treatment 
Patients were treated with IL2 at a dose of 7.8 MIU/m'/d by continuous 
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Table I. Patient characteristics 
Number of patients 51 
Age 
median 49 
range 21-72 
Sex 
male 29 (57%) 
female 22 (43%) 
Performance status (Karnofsky) 
median 90 
range 70-100 
Prior therapy 
none 25 (49%) 
chemotherapy 19 (37%) 
radiotherapy 5 (10%) 
hormone therapy 22 (4%) 
Distribution of metastatic sites 
lung 20 (39%) 
lymph nodes 29 (57%) 
skin 16 (31%) 
liver 17 (33%) 
bone 10 (20%) 
Number of metastatic sites 
1 15 (29%) 
2 14 (27%) 
3 10 (20%) 
4 9 (18%) 
5 2 (4%) 
6 1 (2%) 
infusion on days 1-4 and with IFNa-2a 6 MIU/m'/d by subcutaneous injection on 
day 1 and 4 of each treatment cycle. IL2 (Teceleukin) and IFNa (Roferon-A) were 
supplied by Hoffmann-La Roche Ltd, Basle, Switzerland. Cycles were repeated 
every 2 weeks. 
Evaluation of response was performed after 4 cycles and every 2 months 
thereafter. Patients with response and no change received 9 additional treatment 
cycles. Further continuation of treatment beyond half a year was allowed. 
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Monitoring 
Toxicity was recorded and analysed using the WHO grading system (WHO 
handbook, 1979). Side effects not described in the WHO guidelines were graded 
from mild (grade 1) to life-threatening (grade 4). 
Response was evaluated according to the WHO guidelines (WHO handbook, 
1919). A complete response (CR) was defined as the disappearance of all known 
disease for at least 4 weeks. A partial response (PR) was defined as a reduction 
in the sum of the products of the largest perpendicular diameters of the tumor 
lesions by at least 50% for more than 4. weeks. Stable disease (SD) denoted less 
than 50% tumor reduction and less than 25% tumor progression. Progressive 
disease (PD) was defined as the appearance of a new lesion or an increase in 
size of more than 25% in any lesion. 
RESULTS 
Response 
Of the 51 eligible patients, 24 (47%) received 2-4 treatment cycles, ·12 (24%) 
5-8 cycles, 13 (26%) 9-13 cycles, one patient 15 and one patient 16 cycles. Four 
patients were taken off study early; one due to intercurrent illness and 3 due to 
grade 4 toxicity. 
The overall response rate was 16% (95% confidence interval:7-29%), 
including 1 CR (2%) and 7 PRs (14%). Twenty patients (39%) had stable disease. 
In 23 (45%) patients progressive disease was documented .. Three of the respon-
ders were male and 5 were female. Responses were seen'in skin lesions (36%), 
lymph nodes (27%), lung (18%) and liver (18%). Of note bone metastases did not 
respond. All responses occurred in the first 3 months of treatment. 
The meQian duration of response was 8.2 months (range 4.5-39+ months). 
For all 51 patients the meQlan lime to progression was 2.5 months (range 0.5-39+ 
months). Time to progression for responding patients was 8.2 months (range 4.5-
39+ months), for the patients with stable disease 3.6 months (range 1.7-9.4 
• months) and for progressive disease patients 1.2 months (range 0,5-2.0 months). 
The median survival of all patients was 11.3 months [Figure.1J, and of the respon-
ding patients 20.2 months. 
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Figure 1. Survival curve (median survival 11.3 months). 
Toxicity 
36 48 
An overview of the observed toxicity is presented in Table II. Frequently 
occurring side effects were fever, skin rash, nausea, vomiting, diarrhea and 
malaise. Two-third of patients had tachycardia and hypotension, mostly of mild to 
moderate grade. Life-threatening hypotension requiring vasopressors occurred in 3 
. patients, who were taken off study (see above). One patient developed ventricular 
extra systoles and another patient atrial fibrillation. In a minority of patients 
neurological abnormalities and mental disturbances were seen. Neurotoxicity 
included aphasia, peripheral neuropathy, somnolence, confusion and agitation. 
Two patients required dose reductions because of adverse events and in 8 
patients short interruption of treatment was needed. No toxic death occurred and 
all toxicHies resolved after cessation of immunotherapy. Chronic cumulative fatigue 
occurred after about 3 months of treatment. Consequently only 2 patients did 
receive more than 13 cycles. 
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The most frequent manifestation of haematologic toxicity was anemia (71%). 
Thrombocytopenia was seen in 18% of the patients. Moderate and reversible 
increases in serum creatinine and bilirubin occurred in a minority of patients. 
Table II. Adverse events 
Adverse events Number of WHO grading 
patients (%) 1 2 3 4 
Fever 51 (100) 0 21 30 0 
Skin rash/erythema 36 (71 ) 13 19 4 0 
Nausea/vomiting 48 (94) 7 28 13 0 
Diarrhea 38 (75) 10 20 8 0 
Malaise 29 (57) 4 15 10 0 
Weight gain 15 (30) 13 2 0 0 
Hypotension 39 (76) 7 18 11 3 
Tachycardia 36 (71 ) 13 20 3 0 
Dyspnea 10 (20) 4 4 2 0 
Mental disturbances 8 (16) 5 3 0 0 
Creatinine 19 (37) 16 3 0 0 
Alkaline phosphatase 30 (59) 12 15 3 0 
Bilirubin 9 (18) 7 2 0 0 
Anemia 36 (71 ) 17 14 5 0 
Thrombocytopenia 9 (18) 7 2 0 0 
DISCUSSION 
In this study the combined use IL2 and IFNa in the treatment of metastatic 
melanoma resulted in a 16% response rate, including 2% complete responses. 
These results are disappointing and not belter than can be expected of conventio-
nal chemotherapy or immunotherapy with IL2 alone. 
Response rates of 21-44% have been reported in some studies using the 
combination of both cytokines (Lee et aI., 1989; Rosenberg et aI., 1989b; Budd et 
aI., 1992). However, low response rates of 10% or less were observed by others 
(Oldham et aI., 1992; Dillman et aI., 1993; Sparano et aI., 1993;). The median 
response duration in these trials varied between 2 and 11 months, and the median 
survival was approximately 10 months (Lee et aI., 1989; Rosenberg et aI., 1989b; 
Oldham et aI., 1992; Dillman et aI., 1993; Sparano et aI., 1993). We achieved 
comparable results. 
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We failed to confirm the ability of IFNa to augment the effect of IL2. This may 
have been due to suboptimal dose and schedule. Our patients received moderate 
doses of IL2. In animal studies the efficacy of IL2 is dose dependent without 
reaching a plateau below the maximum tolerated dose (Mule et aI., 1984). 
However, trials using high-dose IL2 (18 MIU/m'/day) by continuous infusion in 
patients with metastatic melanoma reported inferior response rates (Oldham et aI., 
1992; Dillman et aI., 1993). An NCI Surgery Branch Study, administering high-
dose bolus IL2 (>30 MIU/m'/day) and IFNa found the highest response rates 
(Rosenberg et aI., 1989b). On the other hand, the Extramural IL2 Working Group, 
using identical dose, schedule and patient selection criteria did not observe any 
evidence of enhanced response with the IL2/1FNa combination (Sparano et aI., 
1993). Summarizing, a dose-response effect for IL2 in the treatment of metastatic 
melanoma is not clear. 
The side effects, we observed, were of comparable incidence and severity as 
reported earlier (Lee et aI., 1989; Rosenberg et aI., 1989b; Budd et aI., 1992; 
Oldham et aI., 1992; Sparano et aI., 1993). Toxicity was managable and patients 
tolerated the therapeutic regimen relatively well. However, cumulative fatigue 
made it impossible to give patients more than 13 cycles of therapy. 
In conclusion the combined therapy with IL2 and IFNa in the described 
regimen has only moderate activity in the treatment of patients with metastatic 
melanoma. Further clinical trials have to be designed to improve therapeutic 
results. 
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SUMMARY 
We conducted a retrospective study on the incidence of catheter related 
complications and catheter indwelling time (CIT) during treatment wilh continuous 
interleukin-2 (lL2) infusion in patients with metastatic renal cell cancer (RCC), who 
were equipped with tunneled central venous catheters (CVC). 
Seventy-two patients were treated with IL2 based immunotherapy. Two induction 
treatment cycles of 35 days each were used. Treatment consisted of IL2 as a 
continuous intravenous infusion (c.i.v.) with Iymphokine activated killer cells (LAK) 
and interferon-alpha (aIFN) intramuscularly (i.m.). A tunneled CVC was inserted at 
the start of treatment and was kept in place for the duration of the therapy or until 
the occurrence of complications. 
Thirty (42%) of 72 CVCs functioned uneventfully for a median CIT of 64 days. In 
another 12 clinically uncomplicated cases (16%) catheter tips were positive in 
routine culture after a median CIT of 33 days. In 18 patients (25%), CVC related 
infections were noted, including 8 (11%) local tunnel infections and 10 (14%) 
septic episodes. These complications occurred at a median CIT of 28 and 20 
days, respectively. In 15 (83%) of these 18 catheter infections, S.aureus was 
isolated, whereas in the remaining 3 (17%) S.epidermidis was found. 
Subclavian vein thrombosis was noted in 12 (17%) CVCs at a median CIT of 31 
days; 5 (36%) of these were diagnosed in the first 14 patients. This prompted us 
to administer prophylactic heparin 15,000 IU c.i.v. daily during IL2 treatment. 
Thereafter the incidence of thrombosis dropped to 7 (12%) in the subsequent 58 
inserted CVCs (p = 0.03). 
In conclusion, in contrast to previous reports on the high incidence of CVC related 
septicaemia and thrombosis, we observed a relalively low incidence of these 
complications, which we ascribe to the use of tunneled catheters and prophylactic 
heparin. 
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INTRODUCTION 
Interleukin-2 (lL2) is approved for the treatment of metastatic renal cancer. The 
drug has various side effects, which are well characterized (1-3). Because of the 
protracted administration of IL2 and the drug-induced tendency to clotting of 
peripheral veins at the site of infusion, indwelling central venous catheters are 
required. The frequency of CVC related bacterial infections has been reported to 
vary between 10-38% in studies using high dose IL2-regimens (4-6). In all of these 
studies non-tunneled CVCs were used. High dose IL2 appeared to double the 
relative risk of bacteraemia as compared to low dose IL2 regimens, leading to a 
related reduction of catheter indwelling time (CIT) by 40% (4). Skin colonization 
with S. au reus and IL2 induced desquamation of the skin increased the relative 
risk of S. aureus bacteraemia up to 14.5 fold (5). In addition, neutrophil 
dysfunction during IL2 treatment may also contribute to the risk of bacteraemia (7-
9). In our IL2 study protocols, we have used tunneled CVCs to obtain continuous 
vascular access for a prolonged period of time. We selected a tunneled CVC 
procedure because of our previous experience showing a long CIT in immunocom-
promised patients (10). The study reported here presents a retrospective analysis 
of the usefulness of these CVCs as related to catheter infection, catheter related 
sepsis, catheter thrombosis, and CIT in IL2 treated patients. 
PATIENTS AND METHODS 
Eligibility 
Patients with metastatic renal cell carcinoma (RCC) were treated in the framework 
of a phase II study of IL2 based adoptive cellular immunotherapy. Inclusion criteria 
included: measurable or evaluable metastatic RCC, age < 70 years, Karnofsky 
performance status ;" 80, no evidence of brain metastases and normal organ 
functions. Patients with relevant clinical metabolic or endocrine disorders, systemic 
infections, positive HIV or HBsAg serology and patients requiring systemic 
corticosteroids were excluded. All patients gave informed consent according to 
institutional rules. 
Treatment 
IL2 was given as a continuous intravenous infusion (c.i.v.) at a dose of 18 
MIU/m'/day on days 1-5. Lymphapheresis was performed on days 7-9 and 
Iymphokine activated killer (LAK) cells were reinfused in 60 minutes on days 12-15 
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together with IL2 18 MIU/m'/day c.i.v. and interferon-alpha (aIFN) 5 MU/m'/day 
intramuscularly (Lm.) on days 12-16. This cycle was repeated on day 36. After 
these two induction cycles, tumor evaluation was performed. Patients with 
objective response or stable disease continued to receive 4 monthly maintenance 
cycles with IL2 18 MIU/m'/day c.i.v. and alFN 5 MU/m'/day i.m. on days 1-5. After 
17 patients alFN was also administered on days 1-5 of each induction cycle at a 
dose of 5 MU/m'/day i.m. 
Ex vivo activation of lymphocytes with IL2 
We have previously reported the details of this procedure (11). Briefly, all Iymph-
apheresis procedures were performed using a Travenol CS-3000 Blood Cell 
Separator (Travenol, Deerfield, IL). Buffy coats were placed into culture using a 
semi-closed bag system: Travenol-Fenwall PL 732 bags, containing 1500 ml 
activation medium with 3 x 10' cells/6000 IU IL2/ml. Bags were loaded with cells 
and medium using a Travenol-Fenwall model SAY EX 2 Fluid FiIIlWeight Unit. The 
activation medium consisted of RPMI-1640 78%, AIM-V 20% and autologous 
human plasma 2%. L-glutamine-2mM, streptomycin 50 pg/ml, and gentamycin 40 
pg/ml were added to the medium. After incubation for 5 days in a 5% 
carbon dioxide (CO,), humidified, 37"C incubator, cells were harvested on a 
Fenwall Cell Harvester. The harvested cells were washed with saline 0.9% and 
resuspended in human serum albumin 5% supplemented with 6000 IU IL2/ml to a 
volume of 500 ml. 
Surveillance for bacterial contamination of harvested cells involved culturing of 
samples from the culture bags in TCS medium (Gibco Ltd., Buckingham, U.K.): 
a) immediately after Iymphopheresis, 
b) 24 hours prior to cell harvest, and 
c) 1 hour before reinfusing LAK cells into the patient. 
Catheters 
Catheters used were double lumen Hemed CVACs 5200 (11 Fr) (Gish Biomedical 
Inc., Santa Ana, California, USA) and double lumen Groshong CVCs (9.5 Fr) 
(Cath-tech, Salt Lake City, Utah, USA). Both catheters were equipped with a 
Dacron cuff. All catheters were inserted under sterile conditions in the operating 
room by closed method under local anaesthesia by staff surgeons. The subclavian 
vein was the preferred site of insertion and all catheters were tunneled, placing the 
Dacron Cuff at the end of a 15-20 cm subcutaneous tunnel (2 cm from skin entry). 
After the procedure, a chest X-ray was performed to confirm the proper position of 
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the CVC and to rule out the existence of a pneumothorax. Mask and sterile gloves 
were used for all dressing changes, and dressings were changed daily by trained 
nursing personnel. The skin around the catheter was cleansed first with 
chlorohexidine 0.5% in alcohol 70%. Fixomull (Beiersdorf, Hamburg, FRG) was 
placed over sterile gauze on all dressings to cover the insertion site. In between 
treatment courses dressings were changed once a week and catheter lumina were 
flushed with 2 ml of a 0.9% saline solution containing 150 U/ml of heparin. If an 
infection Was suspected or at the end of treatment, catheters were removed in a 
sterile fashion after cleansing the skin surrounding the entry site. The distal 2 cm 
of the catheter was submitted for culture using a semiquantative culture method as 
described by Maki et al. (12). If an infection was suspected, peripheral blood 
samples were drawn via peripheral venous puncture and cultured in TCS medium 
(Gibco Ltd., Buckingham, UK). Skin cultures were taken using a premoistened 
Stuart Culturette (Transwab, MW&E Co. Ltd., Potley, Corsham, Wiltshire, UK). All 
culture samples were incubated both aerobically and anaerobically at 3TC for 72 
hours. 
Definitions 
Catheter related septicaemia was defined as the growth of the same micro-
organisms from the catheter tip and the peripheral blood without evidence of other 
sources of infection. A tunnel infection was defined as tenderness and redness of 
the subcutaneous tunnel with or without evacuation of pus. A positive culture was 
defined as growth of 15 or more bacterial colonies per plate. 
All catheters showing evidence of a tunnel infection were promptly removed, no 
attempts were made to save the catheter by antibiotic treatment. Catheter related 
thrombosis was defined as venous occlusion on angiogram. 
Statistical methods 
To compare variables between two groups the Fisher exact test or the chi-square 
test was used where appropriate. A p-value ,,; 0.05 was considered statistically 
significant. 
RESULTS 
Seventy-two patients were analyzed for the usefulness of their initial CVC. Median 
age of the study population was 54 years. Male : female ratio was 2 : 1. Median 
performance status was Karnofsky 100 (range 80-100). Sixty percent of the 
patients had ;" 2 metastatic organ sites. 
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In 30 patients (42%) the CVCs functioned uneventfully for a median CIT of 64 
days. In other words, these patients received 2 induction treatment cycles using 
one CVC. Twelve CVCs (16%), which were removed routinely because of treat-
ment cessation (median CIT: 33 days), turned out to have positive tips in routine 
culture. There were 18 (25%) infectious episodes: 8 (11%) tunnel infections and 
10 (14%) septicaemias. 
Table 1. CVC and non-CVC related infections 
eVe-related eVe-unrelated 
S.aureus tunnel infections 7(10%1' 
S. aureus sepsis 8 (11 %1 2 (infected LAK culturel (3%1 
S. epidermidis tunnel infection 1 ( 1%1 
S. epidermidis sepsis 2 (3%1 
E.coli sepsis 1 (urinary tract infection) (1 %) 
Routine CVC~tip culture: 
~ S. aureus 4 (5%1 
- S. epidermidis 8 (11%1 
* Percentages related to all 72 patients 
All catheter related infections were caused by staphylococci. S. aureus was the 
isolated micro-organism in 15 (83%) of 18 catheter infections (see table). In 2 
additional patients S. aureus septicaemia was due to contaminated LAK cells, the 
culture results of which became positive on the third day after the start of LAK cell 
reinfusion. S. epidermidis was isolated in 3 (17%) of 18 catheter infections. 
In 12 cases of routine removal of clinically uncomplicated CVCs after 
discontinuation of treatment, routine culture was found to be positive with 4 
cultures showing S. aureus (5%) and 8 cultures showing S. epidermidis (11%). 
Thrombosis of the subclavian vein occurred in 12 (17%) of the 72 CVCs; 5 (36%) 
of these occurred in the first 14 inserted CVCs. Due to this high incidence all 
subsequent patients received prophylactic heparin at a dose of 15,000 IU c.i.v. per 
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24h during IL2 treatment. With this regimen only 7 (12%) thrombotic events were 
observed in the subsequent 58 CVCs (p = 0.03). 
DISCUSSION 
Prolonged central venous access is frequently necessary in cancer patients 
treated with continuous IL2 therapy because of the thrombophlebitis inducing 
potential of IL2. In addition, the i.v. administration of IL2 is often associated with 
hemodynamic changes that require volume replacement and i. v. medication, which 
are usually given via a second lumen of the CVC. 
In view of our previous experience with CVCs in immunocompromised patients 
(10), we have chosen the tunneling procedure for CVC placement in our IL2 
treated patients, since this insertion technique was found to be safe and rapid and 
resulted in a long CIT. In an attempt to further reduce the hazard of CVC related 
sepsis, we used a CVC equipped with a Dacron cuff. Both the Dacron cuff and the 
tunnel are intended to act as a barrier against invading micro-organisms. Of all 
CVCs inserted initially, 42% (30/72) functioned uneventfully for a median CIT of 64 
days. In addition, 16% (12/72) were removed routinely at the end of treatment and 
had thus served their purpose, although routine bacterial culture of the catheter tip 
turned out to be positive. Overall, these results indicate that in 58% of patients 
only one operation for catheter insertion was sufficient, avoiding the risk of 
pneumothorax related to multiple blind CVC insertions. 
The frequency of staphylococcal bacteraemias has been reported to range from 
10-38% in patients receiving IL2 (4-6,9). IL2 related side effects such as transient 
impairment of neutrophil function (7-9), dose dependent incidence of staphylococ-
cal bacteraemia (4), colonization with S. aureus and skin desquamation (5), are 
well documented risk factors for the development of catheter infection and sepsis. 
Richards et al (4) reported a septicaemia incidence of 18% after a mean CIT of 20 
days, associated with low dose (9 MIU/m'/d) IL2 treatment. In case of high-dose 
bolus IL2 (1.8 MIU/kg/d ~ 72 MIU/m'/d) the incidence of septicaemia rose to 38% 
and the mean CIT decreased to 12 days. An uncuffed non-tunneled double lumen 
CVC was used in their patients. Our patients received intermediate doses (18 
MIU/m'/d c.i.v.) of IL2. This dose as a continuous infusion has been shown to be 
equitoxic to bolus administration of 72 MIU/m'/d of IL2 (13). Hence, the relatively 
low incidence of septicaemia of 14% taken together with a long overall median CIT 
of 43 days in our series compare favourably. In a prospective randomized study 
comparing prophylactic oxacillin i.v. with placebo in high dose bolus IL2 (1.8 
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MIU/kg/d) treated patients, Bock et al (6) demonstrated that in the oxacillin arm no 
catheter related septicaemia was seen while in the placebo arm 10% of the 
patients experienced septicaemia (p=0.05). Moreover, catheter colonization was 
reduced significantly in the oxacillin arm (10%) versus placebo arm (44%, 
p=O.0001). To date, in their study CIT was deliberately kept short at ± 4 days and 
therefore their results cannot easily be compared with ours. Moreover, Vlasveld et 
al (14) found 34 (63%) catheter related infections out of a total of 54 CVCs which 
were inserted in cancer patients treated in a phase I-II study with low dose IL2 
(0.18-9 MIU/m'/d) c.i.v. via an implantable Port-a-Cath®. In order to prevent 
infection, subsequent patients received prophylaxis with oxacillin (4 x 1 g Lv. for 
24 hours) starting one hour before CVC insertions followed by oral pefloxacin (1 x 
400 mg daily), given during the entire period of IL2 treatment. These investigators 
could not demonstrate a reduction in the risk of infection by prophylactic anti-
biotics. In contrast, we have found a 14% rate of septicaemia after a median CIT 
of 20 days, despite the fact that we used a much more intensive regimen of 
cytokines without antibiotic prophylaxis, since we wanted to avoid the development 
of bacterial resistance and superinfection related to long-term antibiotic treatment. 
The relatively high rate of catheter related thrombosis observed in the first 14 
patients (36%) might well be attributable to the production of secondary cytokines 
such as tumor necrosis factor-alpha (TN Fa) during IL2 administration (15). Baars, 
et al (16) reported that IL2 activates the coagulation and fibrinolytic systems in 
vivo, which changes resemble the perturbations observed after TNFa administra-
tion. By the institution of prophylactic heparin during IL2 administration the 
frequency of CVC related thrombosis decreased significantly to 12% in the 
subsequent 58 patients (p = 0.03). 
In conclusion, 58% of our patients required only one CVC for the duration of their 
treatment. The infection rate related to the technique of CVC insertion that we 
used, is relatively low in view of the high doses of IL2 used and the avoidance of 
prophylactic antibiotics. This compares favourably to previously reported experi-
ence. Therefore, we recommend the use of this technique in long-term IL2 treat-
ment schedules. Low dose heparine should be given prophylactically to avoid 
thrombotic complications. 
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CONCLUSIES EN PERSPECTIEVEN 
De laatste 20 jaar is er een opleving in de belangstelling voor immunotherapie, 
mede door de recombinant ONA-technieken, de hybridoma technologie en de 
opkomst van de genetische modificatietechnieken. Oit heeft geresulteerd in het ter 
beschikking komen van voldoende hoeveelheden gezuiverde moleculen voor 
onderzoek en therapie bij de mens door middel van cytokinen, hematopoietische 
groeifactoren en monoklonale antilichamen gericht tegen tumor-geassocieerde 
antigenen. Ook de nieuwe mogelijkheden om autologe Iymfocyten ex vivo te 
bewerken tot geactiveerde immuuncellen heeft een stimulans gegeven aan de 
adoptieve immunotherapie. Oit proefschrift beschrijft diverse toedieningsvormen 
van immunotherapie met interleukine-2 (IL2) en combinaties van IL2 en IFN-a met 
of zonder chemotherapie bij de behandeling van solide tumoren. 
Hoofdstuk 1 geeft een uitgebreid overzicht van de reeds toegepaste vormen van 
adoptieve immunotherapie met cytokinen en geactiveerde Iymfocyten bij de 
behandeling van gemetastaseerde nierkanker. De resultaten en beperkingen van 
deze vorm van immunotherapie worden bediscussieerd. Tenslolte worden 
potentieel nieuwe en meer verfijnde methoden van tumorspecifieke 
immunotherapie aangegeven. 
Hoofdstuk 2 beschrijft een fase I-II dosis-escalatie studie waarbij IL2 interpleuraal 
werd toegediend bij mesothelioom. IL2 werd op 14 opeenvolgende dagen 
toegediend. Oit schema werd elke 4 weken herhaald. Partiele responsen (PR) 
werden bij 4 van de 21 evalueerbare patiiinten waargenomen (19%). IL2 spiegels 
in het pleuravocht bleken 6000 maal hoger dan serumspiegels. Tumor necrose 
factor alfa (TNF-a)-spiegels in het pleuravocht, waren zeer variabel en niet 
gecorreleerd aan IL2 doseringen. Mononucleaire cellen in het pleuravocht 
vertoonden bij aile patienten Iymfokine geactiveerde killer (LAK) activiteit. Oosis 
limiterende bijwerkingen werden gezien bij een dosis van 36 MIU IL2 per dag en 
bestonden uit catheter infecties, koorts en griepachtige verschijnselen. Er werd 
geen relatie gevonden tussen dosis en res pons. Op grond van de waargenomen 
bijwerkingen, de afwezigheid van een dosis-respons relatie en het reeds bij lage 
doseringen optredende immunomodulerend effect, werd de aanbevolen IL2 dosis 
voor een fase II studie vastgesteld op 3 MIU per dag. 
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In Hoofdstuk 3 worden de resultaten beschreven van een fase I-II dosis-escalatie 
stud ie, waarbij continue IL2 infusie via de arteria hepatica werd gegeven bij 
patienten met een gemetastaseerd coloncarcinoom met niet-resectabele 
levermetastasen. Bij ongeveer 30% van deze patianten blijkt de lever de enige 
lokalisatie te zijn. De huidige behandelingen met systemische of intra-arteriele 
chemotherapie hebben niet geresulteerd in een betere overleving. Derhalve ligt 
het voor de hand om locoregionale immunotherapie van de lever te bestuderen. In 
onze studie werd via een laparotomie een catheter ingebracht in de arteria 
gastroduodenal is en aangesloten op een Port-a-Cath systeem. Twee weken later 
werd gestart met de intra-arteriale toediening van IL2 gedurende 12 dagen, elke 3 
weken. Een intrapatient dosis escalatie schema werd toegepast met IL2 doserin-
gen varierend van 1.5-12 MIU/m' per dag. Bij doses van 6-12 MIU/m' per dag 
werd aanzienlijke hepatotoxiciteit waargenomen. Trombose van de arteria hepatica 
werd waargenomen bij 2 van de 5 patienten bij de lage dosis IL2 en bij 3 van de 4 
patienten met de hoogste dosis IL2. Door deze complicaties werd de studie 
vroegtijdig gestopt. Geconcludeerd werd dat, als gevolg van de IL2-ge'induceerde 
endotheelschade, kleine arterien zoals de arteria gastroduodenalis, niet geschikt 
zijn voor langdurige IL2 infusie. 
Hoofdstuk 4 beschrijft het antitumor effect en de bijwerkingen bij 44 patienten met 
een gemetastaseerd colon carcinoom. De patienten werden behandeld met IL2, 
IFN-a en 5-FU. Tot op heden is 5-fluorouracil (5-FU) het eniga actieve 
cytostaticum bij deze ziekte. Synergisme tussen 5-FU en IFN-a enerzijds en 
tussen IL2 en IFN-a anderzijds ward aangetoond in preklinische studies en 
aanvankelijk bevestigd in klinische studies bij gemetastaseerd coloncarcinoom, 
melanoom en niercelkanker. Derhalve werd de combinatie van deze 3 middelen 
hier. bestudeerd. De behandeling werd voornamelijk poliklinisch gegeven waarbij 3 
maal per week subcutaan IL2 en IFN-a, en eenmaal per week 5FU intraveneus 
werden toegediend. Er werden 6 (14%) partiele responsen gezien bij 43 evalueer-
bare patienten. De mediane overleving was 47 weken (2-85 weken). De 
bijwerkingen bestonden uit moeheid, misselijkheid en braken. Granulopenie was 
de belangrijkste reden om dosis-uitstel en -reductie toe te passen. Seriale 
bepalingen van fenotypen en cy1oly1ische activiteit van perifere lymfocy1en voor en 
tijdens de therapie toonden geen veranderingen in aantal "natural-killer" cellen en 
de mate van LAK-activiteit. Concluderend heeft de combinatie van IL2 en IFN-a 
met 5-FU slechts een matige antitumor activiteit. 
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Hoofdstuk 5 beschrijft de behandelingsresultaten met IL2 en IFNa bij 57 
gemetastaseerde melanoom pati8nten. De behandeling met IL2 aileen resulteert in 
een responspercentage varierend van 5-27% terwijl met IFN-a een 
reponspercentage wordt bereikt van 12-22%. Op grond van synergistische 
activiteit tussen IL2 en IFN-a, zoals aangetoond in dierexperimenten, en de 
veelbelovende resultaten in vroege klinische studies, hebben we een fase II studie 
gedaan met de combinatie van deze twee middelen. Het behandelschema bestond . 
uit 7,8 MIU IL2/m' per dag toegediend gedurende 4 dagen als continue 
intraveneuze infusie in combinatie met 6 MU IFN-alm' per dag subcutaan op dag 
1 en 4. De kuur werd om de 2 weken herhaald tot een maximum van 13 kuren. 
Van de 51 evalueerbare patienten bereikte 1 (2%) patient een complete respons 
en 7 (14%) een partiele respons. De mediane responsduur was 8 maanden en de 
mediane overleving bedroeg 11 maanden. Cumulatieve chronische moeheid trad 
op na 3 maanden therapie waardoor slechts 2 patienten meer dan 13 kuren 
hebben gekregen. Geconcludeerd kan worden dat deze combinatietherapie slechts 
een matige antitumor activiteit heeft. 
Hoofdstuk 6 beschrijft de resultaten van een retrospectieve stu die naar de 
frequentie van catheter complicaties en catheterisatieduur tijdens de behandeling 
met IL2 bij patienten met gemetastaseerde nierkanker. Hierbij werd IL2 per 
continu infuus via een getunnelde centraal veneuze catheter (CVC) toegediend. 
Om de kans op infectie zo klein mogelijk te houden, werden de CVC's getunneld. 
Na het invoeren van deze methode en het geven van heparine profylaxe 
gedurende de behandeling werd een relatief lage frequentie van infectie en 
catheter gerelateerde trombose waargenomen. 
Perspectieven 
Op grond van de tot op heden gerapporteerde behandelingsresultaten, is het 
duidelijk dat adoptieve immunotherapie met IL2 niet als standaard therapie 
beschouwd kan worden bij de behandeling van solide tumoren. Een nieuwe 
ontwikkeling betreft het maken van tumorspecifieke effector cellen. Alhoewel T-
Iymfocyten voorzien zijn van T-cel receptoren (TCR) die tumor geassocieerde 
antigen en (T M) kunnen herkennen en binden, heeft dit vooralsnog geen klinische 
betekenis omdat tumorcellen vaak hun TM niet adequaat presenteren in de 
groeve van een MHC-molecule, waardoor herkenning door de TCR onmogelijk is. 
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Het CD3 antigen is een activatiemolecule geassocieerd met de TCR. Binding van 
een TAA aan het CD3 molecuul leidt tot activatie van de T-cel, gevolgd door 
Iymfokineproduktie. T -Iymfocyten kunnen op hun doel worden gericht en 
geactiveerd door gebruik te maken van bispecifieke monoklonale antilichamen (bs-
Mab). Dit zijn hybride antilichamen verkregen door fusie van twee afzonderlijke 
Mabs; het ene deel specifiek voor het CD3 antigen en het andere deel specifiek 
voor het T AA van de tumorcel. Het bs-MAb bewerkstelligt kruiskoppeling tussen 
de T-cel en de tumorcel. Hierdoor vindt activatie van de T-cel plaats, hetgeen 
aanleiding geeft tot cytolyse van de tumorcel. Diverse bs-MAbs zijn ontwikkeld met 
specificiteit voor niercelkanker, eierstokkanker en borstkanker. 
Een andere methode om T -Iymfocyten specifiek te richten op een tumorcel is door 
genetische manipulatie van de TCR tot een zogenaamd chimeer immunoglobuline 
T -cel receptor complex (Ig-TCR). Om effectief te zijn behoort een dergelijke T-
Iymfocyt het Ig-TCR deel op een stabiele wijze in associatie met het CD3-antigen 
tot expressie te brengen. Dit wordt bereikt door de introductie en expressie van Ig-
TCR genen, waarbij de variabele gen-segmenten van de TCRa en TCRP ketens 
vervangen worden door de variabele gen-segmenten van de zware en lichte 
ketens van een Ig met bekende specificiteit. Een belangrijk kenmerk van dergelijke 
Ig-TCR Iymfocyten is het vermogen om T AAs te herkennen onafhankelijk van het 
MHC molecule. 
Een andere benadering om een specifieke T-cel respons op te wekken bestaat uit 
immunisatie met tumorcelien waarin cytokinegenen zijn gebracht. Dit resulteert in 
een effectieve concentratie van cytokines in de directe nabijheid van de tumorcel 
en niet elders in het lichaam. Fase I studies met vaccinatie met cytokine-gen 
getransduceerde tumorcelien bij melanoompatienten zijn reeds in gang. Bij deze 
benadering blijft adequate T AA expressie door tumorcelien en hun herkenning een 
probleem. Hoewel het relatief eenvoudig is om cytokine-genen in tumorcelien tot 
expressie te brengen, is dit klaarblijkelijk niet het geval bij Iymfocyten. Het is 
moeilijk om hoge cytokine produktiespiegels te verkrijgen, mogelijk door regulatie 
mechanismen van de Iymfocyt. 
Actieve specifieke immunotherapie met vaccins verkregen uit TAA is conceptueel 
een aantrekkelijke benadering bij de behandeling en mogelijk ook preventie van 
kanker. De gedachte achter dit concept is dat dergelijke vaccins in staat zijn om 
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het immuunsysteem beter te stimuleren en rustende tumorspecifieke T-Iymfocyten 
te activeren. Tot dusver zijn een aantal antigenen ge'identificeerd die herkend 
worden door cytotoxische Iymfocyten. voornamelijk bij melanomen. maar ook bij 
andere tumorsoorten. Vaccinatiestudies met immunogene peptiden bij de mens 
zijn recentelijk van start gegaan. 
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CONCLUSIONS AND PERSPECTIVES 
During the past two decades, renewed interest in immunotherapy was stimulated 
by the results from genetic engineering, improved techniques on protein and 
nucleic acid sequencing and hybridoma technology. Through these techniques, 
highly purified molecules including cytokines, hematopoietic growth factors and 
monoclonal antibodies directed against tumor-associated antigens became 
available for clinical studies. The use of recombinant cytokines to generate, ex 
vivo, autologous lymphocytes with antitumor activity has stimulated the further 
development of adoptive immunotherapy in humans. This thesis describes 
different approaches of immunotherapy with interleukin-2 (IL2), combinations of 
IL2 and interferon-a (IFN-a) with or without the addition of chemotherapy in the 
treatment of solid tumors. 
Chapter 1 gives a comprehensive overview on the applied forms of adoptive 
immunotherapy with cytokines and activated lymphocytes in metastatic renal cell 
cancer (Ree). Furthermore, their results and limitations are discussed. Finally, in 
future perspectives, new and refined methods of tumor specific targeted 
immunotherapy are indicated. 
In Chapter 2 a phase I-II dose-escalation study of locoregionally applied IL2 in 
pleural mesothelioma is reported. IL2 was administered for 14 days, repeated 
every 4 weeks, according to a group-wise dose escalation schedule. Partial 
response (PR) occurred in 4 of 21 evaluable patients (19%). Intrapleural IL2 levels 
were up to 6000-fold higher than systemic levels. Intrapleural tumor necrosis 
factor-alpha (TNF-a) levels varied greatly and did not correlate with the IL2 
dosage. Lymphokine-activated killer (LAK) activity was displayed by intrapleural 
mononuclear cells in all patients. Dose-limiting toxicity was observed at 36 MIU 
IL2 daily, and consisted of catheter infection, fever and flu-like symptoms. No 
relationship between IL2 dose and response was observed. Based on the 
observed toxicity, the lack of a dose-response relationship and the 
immunomodulatory effects seen at relatively low-dose IL2, the recommended IL2 
dose for a phase II study is 3 MIU daily using this treatment schedule. 
Chapter 3 describes the results of a phase I A-B dose-escalation study 
investigating the dose limiting toxicities and antitumor effects of prolonged 
continuous hepatic artery infusion with IL2 in unresectable liver metastases of 
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patients with colorectal cancer. In as many as 30% of colorectal cancer patients 
liver metastases encompass the sole site of initial tumor recurrence. So far, 
neither systemic nor local administration of chemotherapy improved survival in this 
disease. These patients can be considered as candidates for locoregional 
immunotherapy. A catheter connected to a Port-a-Cath system was inserted into 
the gastroduodenal artery at laparotomy and 2 weeks later continuous hepatic 
artery infusion (HAl) of IL2 in 2 cycles of 12 days at 3 weeks intervals was started. 
Intrapatient dose escalation was applied. Doses ranged from 1.5-12 IL2 MIU/m2 
daily. Considerable hepatic toxicity was observed at an IL2 dose of 6 MIU/m2 daily. 
Thrombosis of the hepatic artery was observed in 2 of 5 patients at the lower IL2 
dose levels and in 3 of 4 patients at the highest IL2 dose levels. Because of these 
complications the study was stopped prematurely. In conclusion this study 
demonstrates that due to IL2 induced endothelial damage, small caliber arteries 
like the gastroduodenal artery are not suitable for prolonged IL2 infusion. 
Chapter 4 describes the antitumor activity and toxicity of 44 patients with 
metastatic colorectal cancer. The patients were treated with the combination of 
IL2, IFN-a, and 5-fluorouracil (5-FU). To date, 5-FU remains the most active agent 
against this disease. Synergistic interaction between 5-FU with IFN-a at one hand, 
and between IL2 with IFN-a on the other hand, were demonstrated in preclinical 
studies and appeared to be confirmed in early clinical studies in colorectal cancer, 
metastatic melanoma and RCC. Consequently, the combination of these 3 drugs 
were studied in this disease. The treatment was given predominantly on an 
outpatient basis with three times per week subcutaneous IFN-a and IL2 followed 
by once a week 5-FU as a bolus intravenous injection. There were 6 (14%) PRs 
among 43 evaluable patients. The median overall survival was 47 weeks (range 2-
85 weeks). Toxic effects included fatigue, nausea and vomiting. Granulocytopenia 
was the main reason for dose reductions or treatment interruptions. Serial 
assessments before and during therapy of immunophenotyping and cytolytic 
activities of peripheral blood lymphocytes did not show changes in the numbers of 
circulating natural killer cells or in the levels of LAK activities. It can be concluded 
that the schedule of IL2 and IFN-a combined with 5-FU has only modest antitumor 
activity. 
Chapter 5 describes the results of 57 patients with metastatic melanoma treated 
with IL2 and IFN-a. Immunotherapy with IL2 has been reported to yield a 5-27% 
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response rate in metastatic disease while IFN-a alone has shown response rates 
of 12-22%. Based on synergistic activity of IL2 and IFN-a in preclinical 
experiments and promising results of early clinical trials, we performed a phase " 
study with this combination. The treatment schedule consisted of IL2 given at a 
dose of 7.8 MIU/m'/day for 4 days as a continuous intravenous infusion in 
combination with IFN-a 6 MIU/m'/day subcutaneously on days 1 + 4. The cycle 
was repeated every 2 weeks for a maximum of 13 cycles. Of the 51 evaluable 
patients, 1 (2%) achieved a complete response (CR) and 7 (14%) a PRo The 
median response duration was 8 months and the median survival was 11 months. 
Chronic cumulative fatigue occurred after 3 months of treatment so that only 2 
patients received more than 13 cycles. In conclusion, this combination therapy has 
only moderate antitumor activity. 
Chapter 6 describes the results of a retrospective study on the incidence of 
catheter complications and catheter indwelling time (CIT) during continuous IL2 
infusion in metastatic RCC patients. To reduce the chance of catheter related 
infection a tunneled central venous catheter (CVC) was used. With the institution 
of tunneled CVCs and prophylactic heparin, we observed a relatively low incidence 
of catheter sepsis and thrombosis. 
Perspectives 
Based on the treatment results of immunotherapy studies as reported in the 
literature, it becomes clear that adoptive immunotherapy with IL2 can not be 
recommended as standard treatment for solid tumors. A new approach comprising 
the development of tumor specific effector cells is needed. Although T-
lymphocytes are equipped with T-cell receptors (TCR) which can recognize and 
bind tumor associated antigens (T AA), this is clinically futile since tumor cells often 
do not express their TAA adequately in association with MHC molecules, which 
makes recognition by the TCR impossible. 
The CD3 antigen is an activation molecule physically associated with the TCR. 
Binding of the CD3 to TAA leads to activation of the T-cell, followed by Iymphokine 
production. T-Iymphocytes can be targeted to tumor cells and activated by the use 
of bispecific monoclonal antibodies (bs-MAb) which are hybrid antibodies 
constructed from two parent MAbs: one specific for the CD3 antigen and the other 
specific for a T AA on the tumor cell. BsMAb mediated cross-linking of the T-cell to 
the tumor cell resulting in activation of the T-cell leading to cytolysis of the tumor 
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cell. Several bs-MAbs have been developed with specificity against RCC, ovarian 
cancer and breast cancer. 
By the construction of a chimeric immunoglobulin T-cell receptor complex (Ig-
TCR), tumor selectivity of T lymphocytes may be obtained. To be effective such T 
lymphocytes would require stable expression of the engineered Ig-TCR at the 
lymphocyte surface and its functional association with the CD3 signal-transducing 
element. This has been achieved by the introduction and expression of chimeric 
IgfTCR genes, in which variable gene segments of the TCRa and TCRP chains 
are replaced by the variable gene segments of the heavy and light chain of an Ig 
with known specificity. 
An essential feature of Ig-TCR targeted lymphocytes is their ability to recognize 
TAA in a MHC-unrestricted manner. 
Another approach to induce a specific T-cell response is by immunization of the 
host with tumor cells transduced with genes encoding for cytokines. These 
cytokines are continuously secreted by the tumor cell resulting in effective 
concentrations in the vicinity of tumor cells but not elswhere in the body. Pilot 
studies of cytokine transfer by vaccination with engineered tumor cells in 
melanoma patients have started. However, with this approach adequate TAA 
expression by tumor cells and their recognition remains a problem. 
Although it has been relatively easy to express cytokine genes in tumor cells, this 
is not the case in lymphocytes. It is difficult to achieve constant high levels of 
cytokine production, which is probably due to regulatory mechanisms. 
Active specific immunotherapy with vaccines constructed of TAA is conceptually 
an attractive approach to treatment and possibly to prevention of cancer. The 
rationale is that such vaccines may be able to stimulate the immune system more 
vigorously and activate silent precursor lymphocytes with tumor specificity. Thus 
far, a number of antigens have been identified as targets for recognition by 
cytotoxic lymphocytes, mostly in melanoma, but also in other tumors types. 
Vaccination studies with immunogenic peptides in humans have recently started. 
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